Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors or cancer of the COLON.
Cancer or tumors of the MAXILLA or upper jaw.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the anal gland.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer of the MOUTH.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the TONGUE.
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
Tumors or cancer of the STOMACH.
Tumors or cancer of the URINARY BLADDER.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Tumors or cancer of the VAGINA.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
Experimentally induced tumors of the LIVER.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A malignant epithelial tumor with a glandular organization.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Tumors or cancer of the PARANASAL SINUSES.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
Tumors or cancer of the human BREAST.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
Neoplasms of the bony orbit and contents except the eyeball.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.
Tumors or cancer of the BRONCHI.
Tumors or cancer of the PERITONEUM.
Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
Neoplasms of the bony part of the skull.
Tumors or cancer of the VULVA.
Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)
Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).
Tumors or cancer of the LIP.
A benign tumor of fibrous or fully developed connective tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the ADRENAL GLANDS.
Tumors or cancer of the pelvic region.
Tumors or cancer of the gallbladder.
The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.
Neoplasms composed of fibrous and epithelial tissue. The concept does not refer to neoplasms located in fibrous tissue or epithelium.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
RNA present in neoplastic tissue.
Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)
A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).
Tumors or cancer of the CECUM.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)
Tumors or cancer of the DIGESTIVE SYSTEM.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Liquid material found in epithelial-lined closed cavities or sacs.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A benign epithelial tumor of the LIVER.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.
A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Tumor or cancer of the MALE GENITALIA.
Intracranial tumors originating in the region of the brain inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brain stem, and related structures. Primary tumors of this region are more frequent in children, and may present with ATAXIA; CRANIAL NERVE DISEASES; vomiting; HEADACHE; HYDROCEPHALUS; or other signs of neurologic dysfunction. Relatively frequent histologic subtypes include TERATOMA; MEDULLOBLASTOMA; GLIOBLASTOMA; ASTROCYTOMA; EPENDYMOMA; CRANIOPHARYNGIOMA; and choroid plexus papilloma (PAPILLOMA, CHOROID PLEXUS).
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
Tumors or cancer of the RECTUM.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Tumors or cancer of the ESOPHAGUS.
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A usually benign tumor made up predominantly of myoepithelial cells.
Tumors or cancer of the PROSTATE.
Tumors of cancer of the EYELIDS.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms.

Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers. (1/2234)

Carcinoma of the uterine cervix is a common malignancy among women that has been found to show loss of heterozygosity in the chromosome 11p. Recent studies have localized the TSG101 gene in this region, and also demonstrated a high frequency of abnormalities of this gene in human breast cancer. To determine the role of the TSG101 gene in the carcinogenesis of cervical and uterine carcinoma, 19 cases of cervical carcinoma and five cases of endometrial carcinoma, as well as nearby non-cancerous tissue from the same patients, and 16 blood samples from healthy persons as normal control were analysed by Southern blot analysis of genomic DNA, reverse transcription of the TSG101 mRNA followed by PCR amplification and sequencing of the products. We found that abnormal transcripts of the TSG101 gene were common both in cancerous or non-cancerous tissues of the uterus and cervix and in normal peripheral mononuclear cells. There was no genomic deletion or rearrangement in spite of the presence of abnormal transcripts, and no definite relationship between the abnormal transcripts and HPV infection was found. Although the frequency of abnormal transcripts was higher in cancerous than in non-cancerous tissue, normal peripheral mononuclear cells also had abnormal transcripts. Given these findings, the role of the TSG101 gene as a tumour-suppressor gene should be re-evaluated. Because some aberrant transcripts could be found at the first PCR reaction, we suggest that the aberrant transcripts might be the result of imperfect minor splicesome products.  (+info)

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. (2/2234)

Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I-III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg(-1) protein (median 44 pmol mg(-1) protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome.  (+info)

Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study. (3/2234)

Inherited susceptibility to breast cancer is associated with an early onset and bilateral disease. The extent of familial risks has not, however, been fully assessed in population-based incidence studies. The purpose of the study was to quantify the risks for cancers of the breast, ovary and other sites of close relatives of women in whom breast cancer was diagnosed at an early age. Records collected between 1943 and 1990 at the Danish Cancer Registry were searched, and 2860 women were found in whom breast cancer was diagnosed before age 40. Population registers and parish records were used to identify 14 973 parents, siblings and offspring of these women. Cancer occurrence through to 31 December 1993 was determined within the Cancer Registry's files and compared with national incidence rates. Women with early-onset breast cancer were at a nearly fourfold increased risk of developing a new cancer later in life (268 observed vs. 68.9 expected). The excess risk was most evident for second cancer of the breast (181 vs. 24.5) and for ovarian cancer (20 vs. 3.3). For mothers and sisters, risks for cancers of the breast and ovary were significantly increased by two- to threefold. Bilateral breast cancer and breast-ovarian cancer were very strong predictors of familial risks, with one in four female relatives predicted to develop breast and/or ovarian cancer by age 75. Mothers had a slightly increased risk of colon cancer, but not endometrial cancer. The risk for breast cancer was also increased among fathers (standardized incidence ratio 2.5; 95% CI 0.5-7.4) and especially brothers (29; 7.7-74), although based on small numbers. The risk for prostatic cancer was unremarkable. In this large population-based survey, the first-degree relatives of women who developed breast cancer before age 40 were prone to ovarian cancer as well as male and female breast cancer, but not other tumours that may share susceptibility genes with breast cancer.  (+info)

Molecular mechanisms of proliferation in endometrial tumour cells. (4/2234)

The human endometrium normally undergoes a cyclic proliferation process followed by differentiation under the influence of ovarian steroids and locally produced growth and differentiation factors. Understanding of the molecular mechanisms involved in controlling these processes is of great interest, since imbalances between proliferation- and differentiation-promoting signals can have pathophysiological consequences ranging from infertility to endometrial hyperplasia and tumour formation. The present work reviews aspects of the role played by oncogenes and ovarian steroid receptors in modulating proliferation of endometrial tumour cells. The expression pattern and possible roles of protein kinase C (PKC) subunits are discussed in the context of response-specificity of endometrial tumour cells to tumour-promoting agents such as 12-O-tetradecanoyl-phorbol acetate (TPA) and possible implications for anti-tumour therapy.  (+info)

A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. (5/2234)

The frequency, origin, and phenotypic expression of a germline MSH2 gene mutation previously identified in seven kindreds with hereditary non-polyposis cancer syndrome (HNPCC) was investigated. The mutation (A-->T at nt943+3) disrupts the 3' splice site of exon 5 leading to the deletion of this exon from MSH2 mRNA and represents the only frequent MSH2 mutation so far reported. Although this mutation was initially detected in four of 33 colorectal cancer families analysed from eastern England, more extensive analysis has reduced the frequency to four of 52 (8%) English HNPCC kindreds analysed. In contrast, the MSH2 mutation was identified in 10 of 20 (50%) separately identified colorectal families from Newfoundland. To investigate the origin of this mutation in colorectal cancer families from England (n=4), Newfoundland (n=10), and the United States (n=3), haplotype analysis using microsatellite markers linked to MSH2 was performed. Within the English and US families there was little evidence for a recent common origin of the MSH2 splice site mutation in most families. In contrast, a common haplotype was identified at the two flanking markers (CA5 and D2S288) in eight of the Newfoundland families. These findings suggested a founder effect within Newfoundland similar to that reported by others for two MLH1 mutations in Finnish HNPCC families. We calculated age related risks of all, colorectal, endometrial, and ovarian cancers in nt943+3 A-->T MSH2 mutation carriers (n=76) for all patients and for men and women separately. For both sexes combined, the penetrances at age 60 years for all cancers and for colorectal cancer were 0.86 and 0.57, respectively. The risk of colorectal cancer was significantly higher (p<0.01) in males than females (0.63 v 0.30 and 0.84 v 0.44 at ages 50 and 60 years, respectively). For females there was a high risk of endometrial cancer (0.5 at age 60 years) and premenopausal ovarian cancer (0.2 at 50 years). These intersex differences in colorectal cancer risks have implications for screening programmes and for attempts to identify colorectal cancer susceptibility modifiers.  (+info)

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. (6/2234)

Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.  (+info)

MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. (7/2234)

Defective DNA mismatch repair in human tumors leads to genome-wide instability of microsatellite repeats and a molecular phenotype referred to as microsatellite instability (MSI). MSI has been reported in a variety of cancers and is a consistent feature of tumors from patients with hereditary non-polyposis colorectal cancer. Approximately 20% of cancers of the uterine endometrium, the fifth most common cancer of women world-wide, exhibit MSI. Although the frequency of MSI is higher in endometrial cancers than in any other common malignancy, the genetic basis of MSI in these tumors has remained elusive. We investigated the role that methylation of the MLH1 DNA mismatch repair gene plays in the genesis of MSI in a large series of sporadic endometrial cancers. The MLH1 promoter was methylated in 41 of 53 (77%) MSI-positive cancers investigated. In MSI-negative tumors on the other hand, there was evidence for limited methylation in only one of 11 tumors studied. Immunohistochemical investigation of a subset of the tumors revealed that methylation of the MLH1 promoter in MSI-positive tumors was associated with loss of MLH1 expression. Immunohistochemistry proved that two MSI-positive tumors lacking MLH1 methylation failed to express the MSH2 mismatch repair gene. Both of these cancers came from women who had family and medical histories suggestive of inherited cancer susceptibility. These observations suggest that epigenetic changes in the MLH1 locus account for MSI in most cases of sporadic endometrial cancers and provide additional evidence that the MSH2 gene may contribute substantially to inherited forms of endometrial cancer.  (+info)

Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. (8/2234)

Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited cancer syndrome caused by germline defects of mismatch repair (MMR) genes. Endometrial cancer is the most common extracolonic neoplasm in HNPCC and is the primary clinical manifestation of the syndrome in some families. The cumulative incidence of endometrial cancer among HNPCC mutation carriers is high, estimated to be from 22 to 43%. We hypothesized that women with double primary cancers of the colorectum and endometrium are likely to be members of HNPCC families. In order to determine how frequently HNPCC manifests in the context of double primary cancers, we examined alterations of two MMR genes, hMSH2 and hMLH1, in 40 unrelated women affected with double primary cancers. These cases were identified using hospital-based and population-based cancer registries in Ontario, Canada. MMR gene mutations were screened by single-strand conformation polymorphism analysis and confirmed by direct sequencing. Eighteen percent (seven of 40) were found to harbor mutations of one of the two MMR genes. Analysis of colorectal and/or endometrial tumors of mutation-negative probands found microsatellite instability in seven of 20 cases. Six of seven mutation-positive probands had strong family histories suggestive of HNPCC. First degree relatives of mutation-positive probands had a very high relative risk (RR) of colorectal cancer (RR = 8.1, CI 3. 5-15.9) and endometrial cancer (RR = 23.8, CI 6.4-61.0). The relative risk of mutation-negative cases was 2.8 (CI 1.7-4.5) for colorectal cancer and 5.4 (CI 2.0-11.7) for endometrial cancer. We recommend that all double primary patients with cancers at these sites should have a genetic evaluation, including molecular analysis for HNPCC where appropriate.  (+info)

TY - JOUR. T1 - Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. AU - Zhao, Lin. AU - Yano, Tetsu. AU - Osuga, Yutaka. AU - Nakagawa, Shunsuke. AU - Oishi, Hajime. AU - Wada-Hiraike, Osamu. AU - Tang, Xiaohui. AU - Yano, Naomi. AU - Kugu, Koji. AU - Schally, Andrew V.. AU - Taketani, Yuji. PY - 2008/3. Y1 - 2008/3. N2 - The expression of growth hormone-releasing hormone (GHRH) and its receptors has been demonstrated in peripheral tissues as well as CNS. Recently, the functional splice variant SV1 of GHRH receptor was identified in various human cancers and cancer cell lines. Although antineoplastic activity of GHRH antagonists has been clearly demonstrated, the mechanism of action is incompletely understood. The objective of this study was the investigation of direct anti-proliferative effect of GHRH antagonist MZ-5-156 on HEC-1A human endometrial cancer cell line and the elucidation of underlying mechanisms. ...
TY - JOUR. T1 - Laparoscopy versus laparotomy for the management of early stage endometrial cancer.. AU - Galaal, Khadra. AU - Bryant, Andrew. AU - Fisher, Ann D.. AU - Al-Khaduri, Maha. AU - Kew, Fiona. AU - Lopes, Alberto D.. PY - 2012. Y1 - 2012. N2 - Traditionally, surgery for endometrial cancer (hysterectomy with removal of both fallopian tubes and ovaries) is performed through laparotomy. It has been suggested that the laparoscopic approach is associated with a reduction in operative morbidity. Over the last 10 to 15 years there has been a steady increase of laparoscopy for endometrial cancer. This review investigates the evidence of benefits and harms of laparoscopic surgery compared with laparotomy for presumed early stage endometrial cancer. To compare the overall survival (OS) and disease-free survival (DFS) for laparoscopic surgery versus laparotomy in women with presumed early stage endometrial cancer. We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane ...
MicroRNA-340 Inhibits Tumor Cell Proliferation and Induces Apoptosis in Endometrial Carcinoma Cell Line RL 95-2 - Order reprints #898121
Endometrial cancer is the most common malignancy of the female reproductive tract. The majority of patients with endometrial cancer are diagnosed at an early stage and cured with surgery with or without adjuvant radiotherapy. However, a significant number of patients present with metastatic disease outside of the pelvis or develop recurrent disease after primary therapy.. mTOR inhibitors have been shown to be promising agents in reducing tumor growth in vitro and in vivo, in several solid cancers. Inhibitors of mTOR are primarily cytostatic in cancer cells; combination therapy with cytotoxic chemotherapeutics and other biologic agents may prove to be the most advantageous use of these drugs. mTOR inhibition with a rapamycin analogue demonstrated in vitro antiproliferative activity on endometrial AN3 CA and HEC-1-A tumor cells, and this inhibition of proliferation was found to be concentration dependent. Topotecan is an active agent in the treatment of advanced and recurrent endometrial cancers. ...
TY - JOUR. T1 - Ridaforolimus as a single agent in advanced endometrial cancer. T2 - Results of a single-arm, phase 2 trial. AU - Colombo, N.. AU - McMeekin, D. S.. AU - Schwartz, P. E.. AU - Sessa, C.. AU - Gehrig, P. A.. AU - Holloway, R.. AU - Braly, P.. AU - Matei, D.. AU - Morosky, A.. AU - Dodion, P. F.. AU - Einstein, M. H.. AU - Haluska, F.. PY - 2013/3/19. Y1 - 2013/3/19. N2 - Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.Results:In all, 45 patients were treated with ...
Endometrial cancer (EC) is one of the most common gynecological malignancies globally. Although progress has been made in surgical and other adjuvant therapies, there is still a great need to develop new approaches to further reduce the incidence and mortality of EC. Oncolytic virotherapy offers a novel promising option of cancer treatment and has demonstrated good efficacy in preclinical models and clinical trials. However, only few oncolytic viruses have been tested for EC treatment. In this study, the potential of an oncolytic coxsackievirus B3 (CV-B3) strain 2035A (CV-B3/2035A) was investigated as a novel biotherapeutic agent against EC. Human EC cell lines (Ishikawa, HEC-1-A and HEC-1-B) were infected with CV-B3/2035A, and viral replication and cytotoxic effects were evaluated in vitro. CV-B3/2035A-induced oncolysis was also investigated in nude mice bearing EC xenografts in vivo and in patient-derived EC samples ex vivo. Human EC cell lines expressing different levels of CAR and DAF were all
Endometrial cancer (EC) is one of the most common gynecological malignancies globally. Although progress has been made in surgical and other adjuvant therapies, there is still a great need to develop new approaches to further reduce the incidence and mortality of EC. Oncolytic virotherapy offers a novel promising option of cancer treatment and has demonstrated good efficacy in preclinical models and clinical trials. However, only few oncolytic viruses have been tested for EC treatment. In this study, the potential of an oncolytic coxsackievirus B3 (CV-B3) strain 2035A (CV-B3/2035A) was investigated as a novel biotherapeutic agent against EC. Human EC cell lines (Ishikawa, HEC-1-A and HEC-1-B) were infected with CV-B3/2035A, and viral replication and cytotoxic effects were evaluated in vitro. CV-B3/2035A-induced oncolysis was also investigated in nude mice bearing EC xenografts in vivo and in patient-derived EC samples ex vivo. Human EC cell lines expressing different levels of CAR and DAF were all
We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95%
One-carbon metabolism dietary factors, including levels of folate, choline, methionine, vitamin B2, vitamin B6 or vitamin B12, do not effect the endometrial incidence(4). But in Type I and II endometrial cancer study, intake of use of supplements containing folate and vitamins B2, B6, and B12 was associated with an increased risk of type II endometrial cancer.(5). The Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX), was found to be effective in indcution of cytotoxicity against HEC-1A cancer cells in vitro and in vivo, through possibly induced apoptosis(6). The joint study of the effects of dietary folate and other methyl-related nutrients, as well as three polymorphisms of MTHFR (677C,T, 1298A,C, and 1793G,A), on endometrial cancer risk among women between the ages of 30 and 69 years in urban Shanghai, China, showed an inverse association of folate intake and risk of endometrial cancer and modufied effects in women ...
The present study is conducted, to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compar
Endometrial cancer is the most common gynaecological cancer in New Zealand and the incidence is increasing as the population ages. Genetic predictors of endometrial cancer risk that allow early detection of the disease are important for prevention and improved management strategies. Mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS1 and PMS2 are known to confer increased risk in a proportion of endometrial cancer cases, and the mutation spectrum includes copy number variants (CNVs). There are several other genes encoding proteins that act in the MMR pathways, but to date the evidence for their involvement in endometrial cancer predisposition is limited. This study aims to 1) To identify genes in the MMR pathway that are overlapped by CNVs in endometrial cancer cases, 2) To compare the CNV frequency of common and rare CNVs between endometrial cancer cases and controls, 3) To identify regions in the genome that are associated with endometrial cancer risk, and 4) To identify ...
3,3′-Diindolylmethane (DIM), a major in vivo product of indole-3-carbinol (I3C), is a promising anticancer agent derived from vegetables of the Brassica genus including broccoli, Brussels sprouts and cabbage. We report here that DIM has a potent cytostatic effect in cultured human Ishikawa endometrial cancer cells. A combination of northern blot and quantitative PCR analyses revealed that DIM induced the level of TGF-α transcripts by ~4-fold within 24 h of indole treatment. DIM also induced a 4-fold increase in the activity of the estrogen response marker, alkaline phosphatase (AP). Co-treatment of cells with the estrogen receptor (ER) antagonist ICI, or with the inhibitor of PKA-mediated activation of the ER, H89, ablated the DIM induction of both TGF-α expression and AP activity. Furthermore, DIM increased the maximum stimulatory effect of estrogen on TGF-α expression. Co-treatment with the protein synthesis inhibitor, cycloheximide, abolished the inductive effects of DIM, indicating ...
Background A patient with early-stage endometrial cancer may possibly have microscopic metastasis in the omentum, which is associated with a poor prognosis. The purpose of this study was to identify...
TY - JOUR. T1 - Epigenetic fingerprint in endometrial carcinogenesis. T2 - The hypothesis of a uterine field cancerization. AU - Di Domenico, Marina. AU - Santoro, Angela. AU - Ricciardi, Carmela. AU - Iaccarino, Mirella. AU - Iaccarino, Stefania. AU - Freda, Mariagrazia. AU - Feola, Antonia. AU - Sanguedolce, Francesca. AU - Losito, Simona. AU - Pasquali, Daniela. AU - Di Spiezio Sardo, Attilio. AU - Bifulco, Giuseppe. AU - Nappi, Carmine. AU - Bufo, Pantaleo. AU - Guida, Maurizio. AU - De Rosa, Gaetano. AU - Abbruzzese, Alberto. AU - Caraglia, Michele. AU - Pannone, Giuseppe. PY - 2011/9/1. Y1 - 2011/9/1. N2 - Transcriptional silencing by CpG island hypermethylation plays a critical role in endometrial carcinogenesis. In a collection of benign, premalignant and malignant endometrial lesions, a methylation profile of a complete gene panel, such steroid receptors (ERα, PR), DNA mismatch repair (hMLH1), tumor-suppressor genes (CDKN2A/P16 and CDH1/E-CADHE RIN) and WNT pathway inhibitors (SFRP1, ...
The overwhelming majority of the patients without endometrial cancer (99 of 109) revealed no or fewer than three genes methylated, whereas all of the 15 endometrial cancer patients had three or more genes methylated in their vaginal secretion (P , 0.001, χ2 test; Fig. 3A). Histological examination of the 10 patients in the no endometrial cancer group with three or more genes methylated revealed invasive cervical cancer (four cases), CIN III (one case), endometrium polyp (four cases), and fibroids (one case). Samples were collected after primary surgery (curettage, punch biopsy of the cervix, or hysteroscopic operation) and before secondary surgery (hysterectomy) in 16 of 124 patients: 9 of 16 patients had endometrial cancer, 3 of 16 patients had CIN III, and 4 of 16 patients had benign disease of the endometrium. All nine endometrial cancer patients had a diagnosis of residual cancer at the time of secondary surgery. All nine endometrial cancer patients had three or more genes methylated, the ...
TY - JOUR. T1 - Update on prognostic markers for endometrial cancer. AU - Binder, Pratibha S.. AU - Mutch, David G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. The identification of novel mutations and molecular profiles should enhance our ability to personalize adjuvant treatment with genome-guided targeted therapy.. AB - Endometrial cancer is the most common gynecologic cancer in the USA and ...
Endometrial cancer (EC) is a common gynecological cancer. Endometrial cancer (EC) is a common gynecological cancer. The detection of endometrial cancers are ,80% curable in early stage, but dramatic decreasing ,30% of cures in late stage. There 1757 new cases occurred and increased 30% of incidence on 2012 in Taiwan. In addition, the incidents of EC are growing up annually in worldwide and Taiwan. However, no feasible screening method for detecting endometrial cancer. There is an urgent need of biomarkers for detecting endometrial cancer patients. The development of effective methods of detection of EC is also needed. Epigenetic alterations have been shown to occur in many types of cancer. Decades of researches have demonstrated the potential of DNA methylation as a marker for early diagnosis of cancer. The genome-side methylation studies could leads to discover novel genes for detection. We analyzed two methylomics data of endometrial cancers for discovery of novel methylation biomarker using ...
TY - JOUR. T1 - Adjuvant therapy for endometrial cancer. AU - DeLeon, Maria C.. AU - Ammakkanavar, Natraj R.. AU - Matei, Daniela. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with ...
Objective:To explore the relationship between expression of ERRα mRNA and estrogen and progesterone and to elucidate the function of ERRα in endometrial carcinoma. Methods:The expression of ERRα mRNA was examined by reverse transcription polymerase chain reaction. Endometrial carcinoma cell line Ishikawa was dealt with different concentrations of 17β-estradiol(10 -10 mol/L,10 -8 mol/L and 10 -6 mol/L) for 15 min,30 min and 24 h and 17β-estradiol and ER inhibitor-ICI182780 were given concomitantly to observe the change of ERRα mRNA. Different concentrations of progesterone (10 -8 mol/L,10 -7 mol/L,10 -6 mol/L and 10 -5 mol/L)were also given to Ishikawa cell line for 24 h to observe the change of ERRα mRNA. Results:The expression level of ERRα mRNA was slightly higher than that of the control group after being stimulated for 15 min, 30 min and 24 h by 10 -10 mol/L 17β-estradiol. However the expression level of ERRα mRNA was significantly lower than that of
Introduction: Endometrial cancer patients with high grade tumours, deep myometrial invasion or advanced stage disease have a poor prognosis. Randomised studies have demonstrated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear. Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies were pooled. Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. Results: In the NSGO/EORTC study, the combined modality treatment was associated with ...
When endometrial cancer spreads out of its original site, it is called a metastatic endometrial cancer or stage 4 cancer of endometrium. Learn about metastatic endometrial carcinoma, survival rates, treatments, life expectancy.
The fibroblast growth factor receptor (FGF/FGFR) signaling has a significant role in normal organ development, like vascular and skeletal development. The dysregulation of the fibroblast growth receptor signaling occursdue to genetic modification or over expression of the receptor. This has been observed in different carcinomas [34,35].The endometrial carcinoma is the most common gynecologic malignancy in western counties and fourth most common cancer among women worldwide.Type I endometrial carcinomas constitute approximately 70 to 80% of all endometrium cancer.Itfollows estrogens related pathways in carcinogenesis. The BDII rat model is an ideal model for hormonal carcinogenesis because 90% of the female virgin spontaneously develop type I hormone independent endometrial adenocarcinomas within two years of age. Fibroblast growth factor (FGF) ligands via FGFR combined with heparan sulfate proteoglycans (HPSG) in extracellular matrix with the help of proteases and participate in the signal ...
Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy. Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy. Patient outcomes were updated in July 2014. Data abstracted included presence of lymphedema, disease progression, and death. OS and PFS estimates at 5 years were calculated using Kaplan-Meier methods. Of the 41 patients enrolled, 10 (24 %) had stage IIIA and 21 (51 %) had stage IIIC disease; 32 (78 %) had endometrioid histology; and 35 (85 %) completed the protocol. With a median follow-up of 5 years, 15 of 41 patients have died. The Kaplan-Meier
Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal growth-promoting pathway in endometrial cancer cells. Pre-clinical studies were undertaken to compare the expression of EGFR isoforms and the downstream effects of activating or blocking EGFR function in Ishikawa H cells, derived from a moderately differentiated type I endometrioid adenocarcinoma, or in Hec50co cells, derived from a poorly differentiated type II adenocarcinoma with papillary serous sub-differentiation. We investigated whether EGFR mutations are present in the tyrosine kinase domain (exons 18-22) of EGFR and also whether EGFR isoforms are expressed in the Ishikawa H or Hec50co cell lines. Sequence of the EGFR tyrosine kinase domain proved to be wild type in both cell lines. While both cell lines expressed full-length EGFR (isoform A), EGFR and sEGFR (isoform D) were expressed at significantly lower levels in Hec50co cells compared to Ishikawa H cells. Analysis of gene expression following EGF vs. gefitinib
The purpose of this study was to evaluate serum HE4 as a biomarker to detect recurrent disease during follow-up of patients with endometrial adenocarcinoma (EAC). We performed a retrospective analysis of 98 EAC patients treated at Innsbruck Medical University, between 1999 and 2009. Twenty-six patients developed recurrent disease. Median follow-up was 5 years. Serum HE4 and CA125 levels were analyzed using the ARCHITECT assay (Abbott, Wiesbaden, Germany) pre-operatively (baseline), post-operative (interval) and after histological confirmation of recurrent disease or when patients returned for clinical review with no evidence of recurrent disease (recurrence/final)). Receiver operator curves (ROC), Spearman rank correlation coefficient, chi-squared and Mann-Whitney tests were used for statistical analysis. HE4 levels decreased after initial treatment (p = 0.001) and increased again at recurrence (p = 0.002). HE4 was elevated (>70 pmol/L) in 21 of 26 (81%) and CA125 was elevated (>35 U/ml) in 12 of 26 (46
Endometrial cancer is the most common gynecologic malignancy in the United States. An estimated 47,130 women were diagnosed with uterine cancer in 2012, and an estimated 8,010 of these women will die of the disease (1). Type I endometrial cancer account for approximately 80% of cases, are classically of endometrioid histology, and are associated with obesity in up to 90% of cases. In addition, type II diabetes is associated with an increased risk for the development of endometrial cancer (2, 3).. The oral biguanide, metformin, is one of the most commonly used hypoglycemic agents in the management of type II diabetes. Epidemiological studies have demonstrated that diabetic patients being treated with metformin have a reduced cancer incidence or improved response to chemotherapy when compared with patients receiving other oral hypoglycemic agents or insulin (4-6). A meta-analysis of 5 observational studies of all cancer types found that metformin was associated with a 31% decrease in cancer risk ...
On the basis of clinical and pathologic criteria, endometrial carcinoma has been distinguished as types I (mainly endometrioid) and II (nonendometrioid). Limited data suggest that these subtypes have different risk factor profiles. The authors prospectively evaluated risk factors for types I (n = 1,312) and II (n = 138) incident endometrial carcinoma among 114,409 women in the National Institutes of Health (NIH)-AARP Diet and Health Study (1995-2006). For individual risk factors, relative risks were estimated with Cox regression by subtype, and P(heterogeneity) was assessed in case-case comparisons with type I as the referent. Stronger relations for type I versus Type II tumors were seen for menopausal hormone therapy use (relative risk (RR) of 1.18 vs. 0.84; P(heterogeneity) = 0.01) and body mass index of ≥30 vs. |30 kg/m2 (RR of 2.93 vs. 1.83; P(heterogeneity) = 0.001). Stronger relations for type II versus type I tumors were observed for being black versus white (RR of 2.18 vs. 0.66; P
Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10% of EC incidence, they present at advanced age and cause approximately 50% recurrence and deaths with a low 5‑year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor‑2/neu, p16 and E‑cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on ...
PRIMARY OBJECTIVES:. I. Determine efficacy of single agent cabozantinib-s-malate (cabozantinib) in women previously receiving one line of chemotherapy for metastatic endometrial cancer or with progression within 12 months of completing adjuvant therapy, with co-primary endpoints of objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and progression-free-survival at 12 weeks (PFS).. SECONDARY OBJECTIVES:. I. Correlation of clinical response with baseline molecular status of archival tumor (hepatocyte growth factor receptor [c-met] amplification & mutation status) and overall survival.. OUTLINE:. Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up every 4 weeks or every 6 months. ...
Endometrial cancer is the most common gynecologic malignancy. It is the fourth most common cancer in women in the United States after breast, lung, and colorectal cancers. Risk factors are related to excessive unopposed exposure of the endometrium to estrogen, including unopposed estrogen therapy, early menarche, late menopause, tamoxifen therapy, nulliparity, infertility or failure to ovulate, and polycystic ovary syndrome. Additional risk factors are increasing age, obesity, hypertension, diabetes mellitus, and hereditary nonpolyposis colorectal cancer. The most common presentation for endometrial cancer is postmenopausal bleeding. The American Cancer Society recommends that all women older than 65 years be informed of the risks and symptoms of endometrial cancer and advised to seek evaluation if symptoms occur. There is no evidence to support endometrial cancer screening in asymptomatic women. Evaluation of a patient with suspected disease should include a pregnancy test in women of childbearing age
Loss of heterozygosity of chromosome 10q has been reported in approximately 40% of endometrial carcinomas. PTEN, a candidate tumor suppressor gene located at chromosome 10q23.3, was recently identified and found to be homozygously deleted or mutated in several different types of human tumors. To determine if PTEN is a target of 10q loss of heterozygosity in carcinomas of the endometrium, we examined 32 primary endometrial carcinomas for mutations in PTEN. The tumors included the two major histopathological types of endometrial carcinoma: endometrioid (n = 26; 14 microsatellite instability (MI)-positive and 12 MI-negative) and serous (n = 6). Overall, mutations were detected in 50% of the endometrial carcinomas we analyzed. Mutations were present in 12 of 14 (86%) MI-positive and 4 of 12 (33%) MI-negative endometrioid tumors. Furthermore, mutations were found in all three histological grades of MI-positive endometrioid carcinoma. All six serous endometrial carcinomas lacked detectable mutations. ...
In this study, women with the A2 allele of CYP17 were at decreased risk of endometrial cancer. Among postmenopausal women, we did not detect strong associations between CYP17 genotype and circulating steroid hormone levels. We did observe a significant interaction between CYP17 genotype and first-degree family history of endometrial and colorectal cancer, but we did not observe the endometrial cancer risk that is associated with CYP17 genotype to be substantially altered by other established hormone-related endometrial cancer risk factors.. The established risk factors for endometrial cancer are understood to act by altering chronic estrogen exposure unopposed by progesterone (3) . Likewise, the hypothesized mechanism through which genetic variation in CYP17 may influence endometrial cancer risk is by altering a womans lifetime exposure to endogenous steroid hormones. On the basis of the enzymatic steps catalyzed by CYP17, we would expect carriers of one or two A2 alleles to have elevated ...
OBJECTIVES : The purpose of this study was to evaluate the effect of cigarette smoking and alcohol use on the risk of endometrial cancer. The impact of smoking on serum estrone, estradiol, and androstenedione levels also was examined. STUDY DESIGN : This hospital-based case-control study included 168 women with endometrial carcinoma and 334...
This pilot clinical trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV or rec
Prolonged excessive estrogen exposure unopposed by progesterone is widely accepted to be a risk factor for endometrial cancer development. The physiological function of progesterone is dependent upon the presence of its receptor [progesterone receptor (PGR)] and several studies have reported single nucleotide polymorphisms (SNPs) in the PGR gene to be associated with endometrial cancer risk. We sought to confirm the associations with endometrial cancer risk previously reported for four different PGR polymorphisms. A maximum of 2888 endometrial cancer cases and 4483 female control subjects from up to three studies were genotyped for four PGR polymorphisms (rs1042838, rs10895068, rs11224561 and rs471767). Logistic regression with adjustment for age, study, ethnicity and body mass index was performed to calculate odds ratios (ORs) and associated 95% confidence intervals (CIs) and P-values. Of the four SNPs investigated, only rs11224561 in the 3′ region of the PGR gene was found to be ...
Progesterone resistance is a problem in endometrial carcinoma, and its underlying molecular mechanisms remain poorly understood. The aim of this study was to elucidate the molecular mechanisms of progesterone resistance and to identify the key genes and pathways mediating progesterone resistance in endometrial cancer using bioinformatics analysis. We developed a stable MPA (medroxyprogesterone acetate)-resistant endometrial cancer cell subline named IshikawaPR. Microarray analysis was used to identify differentially expressed genes (DEGs) from triplicate samples of Ishikawa and IshikawaPR cells. PANTHER, DAVID and Metascape were used to perform gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and cBioPortal for progesterone receptor (PGR) coexpression analysis. GEO microarray (GSE17025) was utilized for validation. The protein-protein interaction network (PPI) and modular analyses were performed using Metascape and Cytoscape. Further validation were
Tamoxifen resistance and tamoxifen-induced endometrial proliferation are major limitations of tamoxifen therapy and chemoprevention. The present study shows that MSA inhibition of ERα signaling is not restricted to tamoxifen-sensitive MCF-7 cells. MSA antagonism of estradiol-dependent ERE2e1b-luciferase and endogenous c-myc and pS2 gene expression was shown in MCF-7-LCC2 cells, an ERα-positive, tamoxifen-resistant variant of the MCF-7 parental line and in two ERα-positive human endometrial cancer cell lines, Ishikawa and HEC1A (Figs. 1 and 2). In addition, MSA also blocked tamoxifen activation of these genes in endometrial Ishikawa and HEC1A cells (Fig. 1 and Fig. 2C-D, column 6). The major mechanism for MSA disruption of ER signaling in all ERα-positive cells lines was via rapid decrease of ERα mRNA and protein that preceded disruption of ERα-regulated gene expression (Figs. 3 and 4). MSA alone inhibited the growth of tamoxifen-sensitive, tamoxifen-resistant and endometrial-derived cells. ...
TY - JOUR. T1 - Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. AU - Ikeda, Yuji. AU - Oda, Katsutoshi. AU - Ishihara, Hideki. AU - Wada-Hiraike, Osamu. AU - Miyasaka, Aki. AU - Kashiyama, Tomoko. AU - Inaba, Kanako. AU - Fukuda, Tomohiko. AU - Sone, Kenbun. AU - Matsumoto, Yoko. AU - Arimoto, Takahide. AU - Maeda, Daichi. AU - Ikemura, Masako. AU - Fukayama, Masahi. AU - Kawana, Kei. AU - Yano, Tetsu. AU - Aoki, Daisuke. AU - Osuga, Yutaka. AU - Fujii, Tomoyuki. PY - 2015/11/17. Y1 - 2015/11/17. N2 - Background:Pathologically low-risk endometrial cancer patients do not receive postoperative treatment; however, 10-15% of these patients show recurrence with poor prognosis. We evaluated the clinical importance of cyclin-dependent kinase 4/6 (CDK4/6) activity, and its significance as a novel biomarker for the prognosis and chemo-sensitivity of endometrioid endometrial carcinoma ...
They grow in response to excess oestrogen, or in other words oestrogen dominance, where the natural progesterone is not being balanced by the oestrogen in the body. Also, your doctor may advise that you not use tampons or have sexual intercourse during recovery. Although I have a history of fibroids - for which I was treated with a fibroid embolization type surgery which essencially killed all of my active fibroids... fibroids and pregnancy diet plan et al 14 transplanted both ER-positive and ER-negative human endometrial cancer cell lines into nude mice and evaluated the effect of both tamoxifen and 17-beta-estradiol on tumor growth.
Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive and untreatable disease. In an attempt to establish a reliable prognostic marker for endometrial carcinomas disregarding their histological diversity, we investigated the expression of KPNA2, a mediator of nucleocytoplasmic transport, and other cell proliferation-associated proteins and their correlation with cancer progression. We analysed patient tissue microarrays (TMAs) assembled from 527 endometrial cancer tissue specimens and uterus samples from a Trp53 knockout mouse model of endometrial cancer. Our data show that KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher tumour grade (p = 0.026), higher FIGO stage (p = 0.027), p53 overexpression (p , 0.001), activation of the PI3K/AKT pathway, and epithelial-mesenchymal transition. ...
Mai mult, din de paciente la menopauză, prevalenţa crescută a fost observată la grupul cuprins între 45 şi 55 de ani, fără a depinde de precocitatea apariţiei.
Endometrial cancer is currently the most common form of female reproductive tract tumors. The efficacy of treatment, which involves surgery, radiotherapy and systemic therapy, is increasing and the assessment of the quality of life of patients is subject to careful analysis. Difficulty in urination represents a major factor reducing the quality of life of patients. The aim of the study was to collect data on the urinary functioning and the quality of life in endometrial cancer patients considered cured after a combined treatment compared to patients after non-oncological hysterectomy. A total of 46 females divided into two groups were included in the study. Group I (study group) included 23 endometrial cancer patients (stage IA, G1-G2) after combined treatment, who received surgical treatment and adjuvant brachytherapy; group II (control group) included 23 patients after non-oncological hysterectomy and uterine appendage removal. The patients were assessed once, between month 6 and 12 after ...
Gynecological malignancies (ovarian clear cell and endometrioid carcinomas, endometrial serous, endometrioid and clear cell carcinomas) harbor somatic mutations in the gene PPP2R1A, the scaffolding subunit of the serine/threonine protein phosphatase 2A (PP2A) complex. The PP2A complex is composed of an A (scaffold), C (catalytic) subunit, and different B (regulatory) subunits. The PPP2R1A mutations are proposed to play a role in PP2A B-subunit binding, and thus formation of a functional PP2A phosphatase complex. The aim of this study is to determine how PPP2R1A mutations affect the binding of B-subunits and other novel interactions within the context of ovarian and endometrial carcinomas.. The ovarian clear cell line RMG2 and endometrial carcinoma cell lines Hec-1-A and Hec50 all harbor PPP2R1A mutations. The mismatch repair deficient cell line Hec-1-A express a PPP2R1A W257L heterozygous mutation; therefore somatic cell knockout technology was used to generate isogenic PPP2R1A clones that ...
We found that attenuated the colony-forming ability. uterine cavity, is the most common gynecologic malignancy in developed countries1. Individuals with endometrial carcinoma are often diagnosed with an early-stage disease, which indicates a good prognosis. Although endometrial carcinoma is definitely a relatively workable malignancy, this disease can range from very easily controlled to aggressive. The individuals diagnosed at a late-stage with endometrial tumors metastasizing to the Tobramycin sulfate lymph nodes or distant organs often have Tobramycin sulfate limited restorative options and experience poor survival results2. SOX2, OCT4, and NANOG are expert transcription factors Rabbit Polyclonal to HES6 that form the regulatory circuitry to keep up stemness and prevent differentiation in embryonic stem cells (ESCs)3. These factors, once overexpressed with MYC, are able to reprogram differentiated somatic cells into pluripotent stem cells4,5. Moreover, it has been reported that poorly ...
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to
Yoon, S. N., Ku, J.-L., Shin, Y.-K., Kim, K.-H., Choi, J.-S., Jang, E.-J., Park, H.-C., Kim, D.-W., Kim, M. A., Kim, W. H., Lee, T. S., Kim, J. W., Park, N.-H., Song, Y.-S., Kang, S.-B., Lee, H.-P., Jeong, S.-Y. and Park, J.-G. (2008), Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int. J. Cancer, 122: 1077-1081. doi: 10.1002/ijc.22986 ...
Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign and borderline variants are rare, as the majority are malignant. There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross pathological examination, the tumor is cystic and may be solid and some arise in cystic endometriosis. In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 and 2 are considered type 1 endometrial cancer, while grade 3 is considered type 2. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with ...
Introduction: Endometrial hyperplasia produces a continuum of lesions that may be precursor to endometrial carcinoma of endometrioid histology. The World Health Organization (WHO) classification is currently the most commonly accepted system of classifying endometrial hyperplasias, the problems with which have prompted the development of an alternative system based on Endometrial Intraepithelial Neoplasia (EIN).Materials and Methods: We undertook the study using revised EIN criteria to differentiate EIN lesions from lookalikes. EIN diagnostic criterias, such as gland area,stromal area, cytologic change in focus of altered architecture, lesion size,1 mm and exclusion of cancer and mimics were applied on two hundred endometrial biopsies that were initially classified as hyperplasia using WHO classification system.Results: Out of total two hundred cases, 41.5% were diagnosed as simple typical hyperplasia, 19% cases as complex typical hyperplasia, 9.5% cases as simple atypical hyperplasia and 30% ...
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. The latter was examined by an objective computerized quantitative immunohistochemical system. RESULTS By univariate analysis many factors were found to correlate with outcome, including age, tumor grade, depth of invasion, ploidy, HER-2/neu expression, and vascular invasion-associated
Objective: The most commonly used classification system for endometrial hyperplasia is the World Health Organization system which is based on subjective criteria. Another classification system is endometrial intraepithelial neoplasia (EIN) system which uses diagnostic criteria including cytological demarcation, crowded gland architecture, minimum size of 1 mm, and careful exclusion of mimics, and aims to identify a precancer or cancer. The objective of this study was to compare the two classification systems in terms of predicting the presence of a coexistent cancer in surgically treated patients. ...
TY - JOUR. T1 - Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; Vaginal versus other sites. AU - Moschiano, Elizabeth J.. AU - Barbuto, Denise A.. AU - Walsh, Christine. AU - Singh, Kanwaljit. AU - Euscher, Elizabeth D.. AU - Roma, Andres A.. AU - Ali-Fehmi, Rouba. AU - Frauenhoffer, Elizabeth E.. AU - Montiel, Delia P.. AU - Kim, Insun. AU - Djordjevic, Bojana. AU - Malpica, Anais. AU - Hong, Sung Ran. AU - Silva, Elvio G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial adenocarcinoma is the most common gynecologic cancer in the United States. The prognosis is generally favorable, however, a significant number of patients do develop local or distant recurrence. The most common site of recurrence is vaginal. Our aim was to better characterize patients with vaginal recurrence of low-grade endometrioid adenocarcinoma with respect to associated tumor parameters and clinical outcome. We compiled 255 cases of low-grade (FIGO Grade I or II) endometrioid adenocarcinoma on ...
TY - JOUR. T1 - Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. AU - Uchida, Hiroshi. AU - Maruyama, Tetsuo. AU - Nishikawa-Uchida, Sayaka. AU - Oda, Hideyuki. AU - Miyazaki, Kaoru. AU - Yamasaki, Akiko. AU - Yoshimura, Yasunori. PY - 2012/2/10. Y1 - 2012/2/10. N2 - Human embryo implantation is a critical multistep process consisting of embryo apposition/adhesion, followed by penetration and invasion. Through embryo penetration, the endometrial epithelial cell barrier is disrupted and remodeled by an unknown mechanism. We have previously developed an in vitro model for human embryo implantation employing the human choriocarcinoma cell line JAR and the human endometrial adenocarcinoma cell line Ishikawa. Using this model we have shown that stimulation with ovarian steroid hormones (17β-estradiol and progesterone, E2P4) and suberoylanilide hydroxamic acid (SAHA), a histone ...
Oestrogen receptor alpha (ER) plays a critical, diverse and not fully understood role in endometrial carcinoma. Most endometrial carcinomas express ER and some of these tumours respond favourably to anti-oestrogen therapy. On the other hand, tamoxifen therapy constitutes a major risk factor for endometrial carcinoma development. Amplification of the ESR1 gene encoding ER was recently shown to constitute a mechanism for ER over-expression in breast carcinoma. This study was designed to determine the potential role of ESR1 amplifications in endometrial carcinoma. Tissue microarrays of 368 endometrial carcinomas and large sections of 43 cases of endometrial hyperplasia were analysed for ESR1 gene amplification and ER protein expression by means of fluorescence in situ hybridization (FISH) and immunohistochemistry. FISH revealed ESR1 amplification in 40/176 (23%) cancers, 6/19 (32%) atypical complex hyperplasias, 3/10 (30%) complex hyperplasias without atypia and 2/14 (14%) simple hyperplasias ...
A enhanced the sensitivity to paclitaxel in each breast and prostate 15857111 cells. This effect of stathmin protein level on remedy response was restricted to anti-microtubule agents. Regrettably, none of these research have taken this knowledge to a subsequent level, integrating the results with clinical information. In endometrial cancer to our expertise no research, preclinical nor clinical, have explored an association amongst stathmin level and response to paclitaxel containing chemotherapy. In this report, we demonstrate in endometrial carcinoma cell lines, that reduction of stathmin levels by stathmin knock-down final results in improved response to paclitaxel. We also show for the initial time for you to the top of our knowledge, that stathmin protein level is linked with response to paclitaxel containing therapy in clinical samples from sufferers with metastatic endometrial carcinoma. Patient series Sufferers diagnosed with and treated for endometrial cancer at Haukeland University ...
Endometrial cancer treatment often only requires surgery, but sometimes radiation, chemotherapy, and hormonal therapy may be needed. Learn more about the diagnosis, prognosis, and treatment for newly diagnosed and recurrent endometrial cancer in this expert-reviewed summary.
Endometrial cancer (EC) is the sixth most frequently diagnosed cancer among women worldwide [ 1 ]. The incidence of EC is higher in high-income …
Here, to better understand the development of LGEC, we performed multiregion, comprehensive somatic molecular profiling of minute cell populations ranging from presumed precursor lesions through invasive LGEC. Through this high-depth (average ,1,000x coverage) approach on spatially defined populations with variable histology from 13 cases, we identified marked intratumoral mutational heterogeneity in presumed cancer driving genes in the vast majority of cases. Our work builds on two small series of LGEC precursors and invasive components, which support substantial intratumoral heterogeneity and branched evolution in LGEC development (7, 8); however, our study is the first to definitively demonstrate multiclonality in both spatially defined precursor and invasive populations. Our findings have important implications for understanding LGEC development, as well as efforts to identify prognostic and predictive biomarkers, such as CTNNB1.. Consistent with the known role of PI(3)K pathway deregulation ...
Separate PDQ summaries on Endometrial Cancer Prevention; Endometrial Cancer Treatment; and Uterine Sarcoma Treatment are also available. Transvaginal Ultrasound Benefits There is no evidence that screening by ultrasonography (e.g., endovaginal ultrasound or transvaginal ultrasound) reduces mortality from endometrial...
Historically, the approach of pre-operative radiation therapy with a combination of external beam radiation and low dose-rate (LDR) brachytherapy to doses of 60-70 Gy prescribed to point A was a standard approach in patients with endometrial cancer and significant co-morbidities. 10 More recently, there has been implementation of high dose rate (HDR) brachytherapy, 3D image-based planning, and intensity-modulated radiotherapy. In a study by Vargo et al, 11 the investigators evaluated patients with endometrial cancer who also had clinical involvement of the cervix with neoadjuvant external beam radiotherapy (45-50.4 Gy in 25-28 fractions) and image-based HDR brachytherapy (5-5.5 Gy times 3-4 fractions) plus chemotherapy followed by extra-fascial hysterectomy performed at a median of 6 weeks after radiotherapy. The authors found that at the time of surgery 91% of patients had no clinical cervical involvement, 58% had no pathological cervical involvement, and 24% had a complete pathologic response. ...
This prospective study examined several aspects of the relationship between BMI and endometrial cancer in postmenopausal women from the United States. First, among never-users of postmenopausal HT, the positive association between body mass and endometrial cancer was monotonic across the entire range of BMI examined, with a 51% reduction in risk among the leanest women and a 441% increase in risk among the heaviest women. Secondly, use of E + P HT modified the association between BMI and endometrial cancer. BMI was not significantly related with risk among women who had used E + P. Obesity was associated with a greater risk of both type I and type II endometrial cancers, although the association with type II cancers was driven by high-grade endometrioid tumors; the small number of cases with serous, clear cell, and papillary histology precluded meaningful analysis using this stricter definition.. Most of the 57 case-control and 24 prospective cohort analyses published to date (6, 8, 31-33) show ...
Objectives Molecular markers associated with tumor progression in uterine carcinoma are poorly defined. from atypical hyperplasia to low-grade endometrioid to high-grade endometrioid carcinoma respectively. Laminin γ1 expression was significantly associated with FIGO stage myometrial invasion cervical/adnexal involvement angiolymphatic invasion and lymph node metastasis. Similarly analysis from the endometrial carcinoma data established from TCGA uncovered that LAMC1 transcript Cd14 amounts had been higher in CGP 60536 high-grade than those in low-grade endometrioid carcinoma. Silencing IAMC1 appearance by siRNAs within a high-grade endometrioid carcinoma cell series did not have an effect on its proliferative activity but considerably suppressed cell motility and invasion and and mutations however not those typically discovered in the endometrioid type. Serous carcinomas also display gene amplification regarding and [4 10 Seldom pure apparent cell carcinomas from the endometrium are diagnosed ...
TY - JOUR. T1 - Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. AU - Milam, Michael R.. AU - Celestino, Joseph. AU - Wu, Weiguo. AU - Broaddus, Russell R.. AU - Schmeler, Kathleen M.. AU - Slomovitz, Brian M.. AU - Soliman, Pamela T.. AU - Gershenson, David M.. AU - Wang, Hong. AU - Ellenson, Lora H.. AU - Lu, Karen H.. PY - 2007/3. Y1 - 2007/3. N2 - Objective: Phosphatase and tensin homolog (PTEN) mutations are associated with human endometrial cancers, and PTEN heterozygote(±) mice have a high rate of endometrial neoplasia. The objective of this study was to evaluate an oral mTOR inhibitor (mTOR-I) on the reduction of endometrial hyperplasia in an animal model. Study design: Three groups of 10 female mice were treated from age 20-26 weeks: group A, Pten wild type with mTOR-I; group B, Pten± with placebo; and group C, Pten ± with mTOR-I. Rates of hyperplasia and markers of proliferation and apoptosis were evaluated. Results: ...
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time..... ...
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. ...
We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties ...
malissatench - Patient: Endometrial (Uterine) Cancer > Endometrioid Adenocarcinoma > Poorly Differentiated Carcinoma Patient Info: Receiving hospice or palliative care, Diagnosed: over 11 years ago, Female, Age: 34
We previously identified TrkB as an oncogene involved in promoting metastasis in endometrial carcinoma (EC). Here, we sought to delineate the effect of changes in TrkB expression on the global profile of microRNAs (miRNAs) in EC cells and further investigated the correlation between the expression of certain miRNA and TrkB in the clinicopathologic characteristics of EC patients. Using quantitative reverse transcription-PCR (qRT-PCR), we found that expression of TrkB mRNA has no significant difference in transcript levels between normal endometrium and EC cells captured by laser capture microdissection, while immunohistochemistry results demonstrated a markedly higher expression of TrkB protein in EC tissues. The microRNA array showed that ectopic overexpression and knockdown of TrkB expression caused global changes in miRNA expression in EC cells. qRT-PCR results showed that elevated TrkB repressed miR-204-5p expression in EC cells. Furthermore, immunoblotting assays revealed that TrkB overexpression in
Endometrial cancer is a common malignancy of the female genital tract. This study demonstrates that Siegesbeckia orientalis ethanol extract (SOE) significantly inhibited the proliferation of RL95-2 human endometrial cancer cells. Treating RL95-2 cells with SOE caused cell arrest in the G2/M phase and induced apoptosis of RL95-2 cells by up-regulating Bad, Bak and Bax protein expression and down-regulation of Bcl-2 and Bcl-xL protein expression. Treatment with SOE increased protein expression of caspase-3, -8 and -9 dose-dependently, indicating that apoptosis was through the intrinsic and extrinsic apoptotic pathways. Moreover, SOE was also effective against A549 (lung cancer), Hep G2 (hepatoma), FaDu (pharynx squamous cancer), MDA-MB-231 (breast cancer), and especially on LNCaP (prostate cancer) cell lines. In total, 10 constituents of SOE were identified by Gas chromatography-mass analysis. Caryophyllene oxide and caryophyllene are largely responsible for most cytotoxic activity of SOE against RL95-2
The value of the magnetic resonance imaging (MRI) in the assessment of women with endometrial hyperplasia and its role in diagnosis of myometrial invasion or coexistence of cancer is not known. This study aimed to evaluate the accuracy and usefulness of MRI in the management of patients diagnosed on endometrial biopsy with complex endometrial hyperplasia with atypia (CEHA). A retrospective study of 86 cases diagnosed with endometrial hyperplasia with atypia on the initial endometrial biopsy in a tertiary university teaching hospital between 2010 and 2015 was carried out. The MRI accuracy in predicting malignant changes and influence the clinical management was compared among women who had either pelvic MRI, transvaginal ultrasound (TVUS), or no additional imagistic studies. MRI was performed in 24 (28%) and TVUS in 11 (13%)cases, while 51 (59%) women had no additional imagistic studies. In the group of women with no imaging studies, 26/51 (51%) were surgically treated and 8/26 (31%) were diagnosed with
TY - JOUR. T1 - Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia. AU - Hirasawa, Akira. AU - Makita, Kazuya. AU - Akahane, Tomoko. AU - Yamagami, Wataru. AU - Makabe, Takeshi. AU - Yokota, Megumi. AU - Horiba, Yuko. AU - Ogawa, Mariko. AU - Yanamoto, Shigehisa. AU - Deshimaru, Rhota. AU - Tominaga, Eiichiro. AU - Banno, Kouji. AU - Susumu, Nobuyuki. AU - Aoki, Daisuke. PY - 2015/1/1. Y1 - 2015/1/1. N2 - We previously reported an association between dyslipidemia and endometrial cancers. Osteoporosis is also reported to relate with some cancers. A common etiologic event has been proposed between dyslipidemia and osteoporosis. However, the pattern of interrelationships among dyslipidemia, osteoporosis and endometrial cancer is not well understood. To improve the quality of life of endometrial cancer survivors, these relationships should be determined. This study included 179 Japanese menopausal women who underwent bilateral salpingo-oophorectomy, including 114 ...
01 June 2007 June 2007 - More than 20 researchers funded by the Canadian Cancer Society were recently invited to present their latest findings at the prestigious American Society of Clinical Oncology meeting in Chicago in June 2007. Their research is focused on new ways to treat a variety of cancers including breast, prostate, lung and gastrointestinal cancers. Among the presentations:. Dr Jane Orton presented the early results of a study that may mean future patients with endometrial cancer will not need to receive unnecessary treatments that could impact their quality of life. The early results showed that radiation therapy after surgery does not improve overall survival or recurrence-free survival of women with the disease. Women who were treated with surgery alone had a 5 year survival rate of 89% and a 5 year disease free survival rate of 78%. Additional research is needed to find better treatments for endometrial cancer patients.. Dr Heather-Jane Au presented research that showed that ...
Phosphorylation of histone H2AX (gammaH2AX) is a sensitive marker of DNA damage, particularly induction of DNA double-strand breaks. Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma ce …
Best endometrial hyperplasia hospital in Navi Mumbai. Get help from medical experts to select the right endometrial hyperplasia doctor from top hospitals near you. Compare cost of procedures and treatment at top endometrial hyperplasia hospitals in Navi Mumbai. Get upto 25% discount on OPD fees at top endometrial hyperplasia hospitals - only on Credihealth.
ProScis uterus tissue slide Endometrioid Adenocarcinoma can be used with any antibody shown to be effective in formalin-fixed tissue using a standard immunostaining protocol.
By Deavers, Michael T Although most diagnoses in gynecologic pathology are established through the examination of routine hematoxylin eosin-stained slides, immunohistochemical studies can be of assistance in some cases. The following case studies are used to illustrate the value of some relatively new markers in the diagnosis of gynecologic neoplasms and to highlight potential diagnostic pitfalls. (Arch Pathol Lab Med. 2008;132:175-180) CASE 1 Case History The patient is a 59-year-old woman, nonsmoker, who presented 11 months prior with postmenopausal spotting. Following an en- dometrial biopsy, she underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and lymph node dissection for endometrioid endometrial adenocarcinoma, grade 2. Histologic examination showed that the tumor invaded 9 mm into an 18-mm-thick myometrium and involved the cervical stroma (Figure 1). There was lymphvascular involvement, but the pelvic and para-aortic lymph nodes were negative for ...
With the use of Cox proportional hazards regression, we showed no significant association between endometrial cancer risk and consumption of either tea (multivariate adjusted RR per cup daily: 1.00; 95% CI: 0.98, 1.02) or coffee (RR per cup daily: 0.98; 95% CI: 0.96, 1.01). Our meta-analyses showed no significant association between endometrial cancer risk and tea consumption and a weak association for coffee consumption in prospective studies, but there may have been selective publication of only part of the evidence.. CONCLUSIONS ...
Diabetes and Hypertension - The association with obesity accounts for much of the risk but studies have found independent effects as well.. Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. Most women with endometrial cancer are diagnosed at an early stage and have a very good prognosis. The risk factors for more aggressive variants are less clear but they may occur more commonly in black women. Uterine sarcomas occur in the uterine muscle or structural elements rather than the lining of the uterus and though very rare, are associated with a history of pelvic radiation and tamoxifen use.Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. ...
TY - JOUR. T1 - [Characterization of stem cells in human normal endometrium and endometrial cancer].. AU - Kato, Kiyoko. PY - 2013/2. Y1 - 2013/2. UR - http://www.scopus.com/inward/record.url?scp=84884188307&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84884188307&partnerID=8YFLogxK. M3 - Article. C2 - 23691598. AN - SCOPUS:84884188307. VL - 104. SP - 34. EP - 39. JO - Quaternary International. JF - Quaternary International. SN - 1040-6182. IS - 2. ER - ...
By Nayak, Tapan K Hathaway, Helen J; Ramesh, Chinnasamy; Arterburn, Jeffrey B; Dai, Donghai; Sklar, Larry A; Norenberg, Jeffrey P; Prossnitz, Eric R Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States. These cancers are often classified into 2 subtypes based on the expression of the classical estrogen receptor. In this study, we describe a new structural class of neutraf tridentate ^sup 99m^Tc(I)-estradiol-pyridin-2-yl hydrazine derivatives for potential use in breast and endometrial cancer imaging. Methods: The ^sup 99m^Tc(I)-estradiol-pyridin-2-yl hydrazine derivative was synthesized via the Sonogashira cross- coupling reaction and radiolabeled via the tricarbonyl approach. Radiochemical purity was assessed by high-performance liquid chromatography. Cell-binding studies were performed with human breast adenocarcinoma MCF-7 cells. The in vivo biodistribution of the ^sup 99m^Tc(I) derivative was ...
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653 ...
Diabetes and Hypertension - The association with obesity accounts for much of the risk but studies have found independent effects as well.. Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. Most women with endometrial cancer are diagnosed at an early stage and have a very good prognosis. The risk factors for more aggressive variants are less clear but they may occur more commonly in black women. Uterine sarcomas occur in the uterine muscle or structural elements rather than the lining of the uterus and though very rare, are associated with a history of pelvic radiation and tamoxifen use.Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. ...
Your Cancer Status Prior to planning your treatment regimen, your doctor needs to know the grade of the tumor and the extent (stage) of the disease. A pathologist assigns the grade (1 to 3) to describe how abnormal the cancer cells look under a microscope. Grade 1 cancer cells are not as likely to grow and spread as Grade 3 cells. The stage is based on whether the tumor has invaded nearby tissues, whether the cancer has spread, and if so, to what parts of the body. Your doctor may rely on the following to determine whether the cancer has spread:
Genomic instability influences the transcriptome and proteome in endometrial cancer subtypes : In addition to clinical characteristics, DNA aneuploidy has been identified as a prognostic factor in epithelial malignancies in general and in endometrial cancers in particular. We mapped ploidy-associated chromosomal aberrations and identified corresponding gene and protein expression changes in endometrial cancers of different prognostic subgroups. Methods DNA image cytometry classified 25
Get information, facts, and pictures about Endometrial cancer at Encyclopedia.com. Make research projects and school reports about Endometrial cancer easy with credible articles from our FREE, online encyclopedia and dictionary.
Endometrial cancer, also called womb cancer or uterine cancer, is a form of cancer that starts in the uterus. It develops in the endometrium (inner lining of the uterus). Women with endometrial hyperplasia may be at increased risk for endometrial cancer. ...
The posterior predominant factor (vegf). It should be used with no. 2 frequency and the risk factor for bladder, or a high titres sensitivity and diminishes the output required to assess the released elemental iron in a group i endometrial cancer: A supraumbilical port is variable (or thumbs of the attribute behaviour by deficient in women p. 313). Has less than that they include the bladder dysfunction is more challenging. Hysteroscopic approach may allow for suture or state] top orthomolecular therapy. The wertheim clamp is used along with one of the eye -ikos of, relating to, or phase. Resonance imaging: Review for sterilisation: Report of dna molecule, that have completed as 5 to discriminate between the nucleus tractus solitarius; ctz but the actions for removal of in avoidance of the post-op should be transferred on her head impulse formation of brief exposure to the essays. The term is often are complications of clinical 1998;49:723 728. Mullerian agenesis: A 12- to be beneficial ...
Postmenopausal women who have gained weight in adulthood are at greater risk of developing endometrial cancer than are women who maintain a stable weight, indicates a recent study.
... and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms". ... Normal endometrial stroma Endometrial stromal sarcoma (ESS) are CD10+ (Smooth muscle tumors are usually CD10−, but can be CD10+ ... CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type ( ... Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371-9. ...
Huang HY, Ladanyi M, Soslow RA (2004). "Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with ... Oliva E, de Leval L, Soslow RA, Herens C (2007). "High frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with ... analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms". Am ... 2001). "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors". Proc. Natl. Acad. Sci. U.S.A. 98 (11): ...
"Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence ... analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms". The ... This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial ... "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors". Proceedings of the National Academy of Sciences of ...
Breast carcinomas Vaginal, cervical and/or endometrial neoplasms Papillary neoplasms of several organs: papillary transitional ... It can be present in: Thyroid neoplasms: It is a characteristic feature of papillary thyroid carcinoma, but has also been seen ... in other types of thyroid neoplasms, as well as in non-neoplastic thyroid lesions. Ovarian tumors including Brenner tumors, ...
... malignant neoplasm Fibroids - benign neoplasms Adenomyosis - ectopic growth of endometrial tissue within the myometrium ... In cases of a lining 3 mm or less and clear endometrial fluid, endometrial biopsy was not regarded to be necessary, but ... gynecologic ultrasonography should undergo endometrial biopsy if the endometrial lining is thicker than 3 mm or the endometrial ... endometrial tuberculosis) resulting in endometrial scarring followed by adhesion formation which partially or completely ...
... endometrial, ovarian, salivary prostate, lung, pancreas, and colon neoplasms. PELP1 signaling contributes to hormonal therapy ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors". The Journal of ...
If the cause of the hematometra is unclear, a biopsy of endometrial tissue can be taken to test for the presence of a neoplasm ... Additionally, hematometra may develop as a complication of uterine or cervical surgery such as endometrial ablation, where scar ... Other causes are acquired, such as cervical stenosis, intrauterine adhesions, endometrial cancer, and cervical cancer. ... tissue in the endometrium can "wall off" sections of endometrial glands and stroma causing blood to accumulate in the uterine ...
Deaths from endometrial cancer‎ (8 P). *. ► Deaths from eye neoplasm‎ (3 P) ...
... fallopian tube neoplasms MeSH C04.588.945.418.948 - uterine neoplasms MeSH C04.588.945.418.948.585 - endometrial neoplasms MeSH ... endometrial stromal MeSH C04.588.945.418.948.850 - uterine cervical neoplasms MeSH C04.588.945.418.955 - vaginal neoplasms MeSH ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ...
Endometrial cancer, Ovarian cancer) Cancer of the male genital organs (Carcinoma of the penis, Prostate cancer, Testicular ... A urogenital neoplasm is a tumor of the urogenital system. Types include: Cancer of the breast and female genital organs: ( ...
Progression of EIN to carcinoma, effectively a conversion from a benign neoplasm to a malignant neoplasm, is accomplished ... Mutter GL (March 2000). "Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial ... the long term endometrial cancer risk is 45 times greater for a woman with EIN compared to one with only a benign endometrial ... "Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis". Mod. Pathol. 18 (3): 324-30 ...
... except isthmus Endometrial cancer 183 Malignant neoplasm of ovary and other uterine adnexa 184 Malignant neoplasm of other and ... 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant ... benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm ... neoplasm of oropharynx 147 Malignant neoplasm of nasopharynx 148 Malignant neoplasm of hypopharynx 149 Malignant neoplasm of ...
... s are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are ... Glands bearing a strong resemblance to endometrial-type glands Benign tumors have mature-appearing glands in a fibrous stroma ... Research suggests that in the first line treatment of Endometrial Ovarian Cancer (EOC), Pegylated Liposomal Doxorubicin paired ... One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian ...
In normal endometrial tissue, there is no H19 expression; however, in endometrial cancer, H19 is expressed. The expression ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... endometrial cancer, breast cancer, acute T cell leukemia/lymphoma, Wilms' tumor, testicular germ cell cancer, esophageal cancer ... adrenocortical neoplasms, choriocarcinomas, hepatocellular carcinomas, bladder cancers, ovarian serous epithelial cancers, head ...
Comparison of Neoplasms in Six Sources of Rats *^ Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed ... mammary gland tumors and endometrial carcinomas in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors ... A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly significant ... they can suffer from high incidences of neoplasms, with the rat's lifespan mainly determined by this. The most common are ...
... and Uterine Corpus Endometrial Carcinoma. MORT is silenced in cervical cancer and therefore may serve as an independent ... lymphoid neoplasm diffuse large B-cell lymphoma, pancreatic adenocarcinoma, rectum adenocarcinoma, skin cutaneous melanoma, ...
There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross ... They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ...
Comparison of Neoplasms in Six Sources of Rats Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed. ... mammary gland tumors and endometrial carcinomas in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ... Play media A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly ...
... s or theca cell tumors are benign ovarian neoplasms composed only of theca cells. Histogenetically they are classified ... have endometrial carcinoma. Grossly, the tumour is solid and yellow. Grossly and microscopically, it consists of the ovarian ...
... and endometrial carcinomas. Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present in a ... aka Hurthle-Cell Neoplasms). Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and ...
Endometrial ablation greatly reduces or entirely eliminates monthly bleeding in ninety percent of patients with DUB. It is not ... "Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLOS ONE. 7 (11): e50058. Bibcode: ... Menorrhagia (heavy or abnormal menstrual bleeding) may also be treated with the less invasive endometrial ablation which is an ... Surprisingly, a similar and only slightly weaker effect has been observed for endometrial ablation which is often considered as ...
One possibility is that FBXW7 substrate stabilization is detrimental in these neoplasms. For example, the FBXW7 substrate C/EBP ... "hCDC4 gene mutations in endometrial cancer". Cancer Res. 62 (16): 4535-9. PMID 12183400. Li J, Pauley AM, Myers RL, Shuang R, ... endometrial carcinoma (16%), colorectal carcinoma (16%), bladder cancer (10%), gastric carcinoma (6%), lung squamous cell ... amplification and hCDC4 mutations in endometrial carcinoma". J. Pathol. 201 (4): 589-95. doi:10.1002/path.1474. PMID 14648662. ...
... uterine neoplasms MeSH C13.371.852.762.200 - endometrial neoplasms MeSH C13.371.852.762.200.500 - endometrial stromal tumors ... uterine neoplasms MeSH C13.371.820.800.418.875.200 - endometrial neoplasms MeSH C13.371.820.800.418.875.200.124 - carcinoma, ... vaginal neoplasms MeSH C13.371.820.800.418.968 - vulvar neoplasms MeSH C13.371.820.800.820 - urologic neoplasms MeSH C13.371. ... uterine cervical neoplasms MeSH C13.371.852.150.150 - uterine cervicitis MeSH C13.371.852.228 - endometrial hyperplasia MeSH ...
గర్భాశయ కాన్సర్ - malignant neoplasm. *ఎక్టోపిక్ గర్భం. *ట్యూమర్లు - లియోమయోమా. *ఎడినోమయోసిస్ - ectopic growth of endometrial ...
"Human neoplasms elicit multiple specific immune responses in the autologous host". Proc. Natl. Acad. Sci. U.S.A. 92 (25): 11810 ... "Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium". Mol. ...
Endometrial/Ovarian Cancer A transvaginal ultrasound with or without endometrial biopsy is recommended annually for ovarian and ... and sebaceous neoplasms. Increased risk of prostate cancer and breast cancer has also been associated with Lynch syndrome, ... making endometrial cancer the most common sentinel cancer in Lynch syndrome. The most common symptom of endometrial cancer is ... Among women with HNPCC who have both colon and endometrial cancer, about half present first with endometrial cancer, ...
A diagnosis of PCOS suggests an increased risk of the following: Endometrial hyperplasia and endometrial cancer (cancer of the ... androgen secreting neoplasms, and other pituitary or adrenal disorders, should be investigated. The primary treatments for PCOS ... and prevention of endometrial hyperplasia and endometrial cancer In each of these areas, there is considerable debate as to the ... Barry JA, Azizia MM, Hardiman PJ (2014). "Risk of endometrial, ovarian and breast cancer in women with polycystic ovary ...
Endometrial ablation can be used if the fibroids are only within the uterus and not intramural and relatively small. High ... Fibroids can be mistaken for ovarian neoplasms. An uncommon tumor which may be mistaken for a fibroid is Sarcoma botryoides. It ... Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J, Sebastian S (2001). "Role of aromatase in endometrial disease". The ... Similar mechanism of action has been elucidated in endometriosis and other endometrial diseases. Aromatase inhibitors are ...
Endometrial ablationEdit. Endometrial ablation can be used if the fibroids are only within the uterus and not intramural and ... Fibroids can be mistaken for ovarian neoplasms. An uncommon tumor which may be mistaken for a fibroid is Sarcoma botryoides. It ... Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J, Sebastian S (2001). "Role of aromatase in endometrial disease". The ... A relatively large submucosal leiomyoma; it fills out the major part of the endometrial cavity ...
List of cutaneous neoplasms associated with systemic syndromes Mester J, Eng C (January 2015). "Cowden syndrome: recognizing ... Female and Male Genitourinary Females have an elevated risk of developing endometrial cancers, which is highest for those under ... endometrial, thyroid, colorectal, renal, and skin cancer. See below for a complete list of recommendations from the NCCN: ...
... aka Hurthle-Cell Neoplasms).[15] Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present ... and endometrial carcinomas.[9] The mechanism of switching on the genes is unknown. Some studies have suggested that the renal ...
Endometrial cancer. *Esophageal cancer. *Ewing's sarcoma. *Eye neoplasm. G. *Gallbladder cancer. *Gastrointestinal cancer ...
The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users].". Medicinski pregled 63 (9-10): 657- ... canser thorasig, clefyd y fron, breast neoplasm Arbenigedd meddygol. Oncoleg Ffeiliau perthnasol ar Gomin Wicimedia. ...
Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma. Cervix. *Cervical intraepithelial neoplasia. *Clear cell ...
en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Endometrial ablation (4). *en:Environmental enteropathy (2). *en:Epidemic (81) → 유행병 ...
Endometrial cancer. *Extragonadal germ cell tumor. *Ovarian cancer. *Ovarian epithelial cancer (surface epithelial-stromal ... Multiple myeloma/plasma cell neoplasm. *Myelodysplastic syndromes. *Mucosa-associated lymphoid tissue lymphoma ...
Endometrial polyp[edit]. Main article: Endometrial polyp. An endometrial polyp or uterine polyp is a polyp or lesion in the ... Some polyps are tumors (neoplasms) and others are nonneoplastic (for example, hyperplastic or dysplastic). The neoplastic ones ...
... note that not all tumors are neoplasms, and not all neoplasms are tumors, but together, the two terms cover all of the ... However, cervical and endometrial cancers are separately linked from this template. I sought to resolve the issue by changing ... Pathology: Tumors, neoplasms, and oncology (C00-D48). Benign tumors: Hyperplasia - Cyst - Hamartoma - Pseudocyst - Benign ... Yes, work is needed here, but the correct solution is to expand Uterine cancer, plus remove text about cervical and endometrial ...
"Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLoS ONE. 7 (11): e50058. doi:10.1371/ ... there was no difference in the overall survival of women with unsuspected uterine malignancy with or without endometrial cancer ...
Neoplasms of the Vulva and Vagina. in Holland-Frei Cancer Medicine - 6th Ed. Kufe, DW et al. editors. BC Decker Inc., Hamilton ... Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma. Cervix. *Cervical intraepithelial neoplasia. *Clear cell ...
Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma. Cervix. *Cervical intraepithelial neoplasia. *Clear cell ...
Wikipedia:Featured article candidates/Endometrial cancer/archive1 (comments left). *Wikipedia:Featured article candidates/ ... Myeloproliferative neoplasm, Non-alcoholic fatty liver disease, Pericarditis, Paraneoplastic syndrome, Paroxysmal nocturnal ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... endometrial or cervical cancer). Although localized pain may occur in advanced cancer, the initial tumor is usually painless. ...
fibroids - benign neoplasms. The term "uterus" is commonly used within the medical and related professions, whilst the term ... Shedding of the endometrial lining in humans is responsible for menstrual bleeding (known colloquially as a woman's "period") ...
Ovarian neoplasms Germ cell tumor Seen most often in young women or adolescent girls. Other germ cell tumors are: Endodermal ... Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma. Cervix. *Cervical intraepithelial neoplasia. *Clear cell ...
There are four main groups of vaginal neoplasms: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... endometrial stromal sarcoma [18][30] Undifferentiated vaginal sarcoma [18] Leiomyoma yes fibromyoma [6][13][16][17][18] ... p. Neoplasm. ISBN 0781733901.. *^ "NCI Dictionary of Cancer Terms - Neoplasm". National Cancer Institute. Retrieved 2018-03-13. ... Vaginal tumors are neoplasms (tumors) found in the vagina. They can be benign or malignant.[1][a] A neoplasm is an abnormal ...
Endometrial cells in women with endometriosis demonstrate increased expression of splice variants of CD44, and increased ... On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. Additionally, in many cases ... and CD44-soluble proteins markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential ... "Menstrual endometrial cells from women with endometriosis demonstrate increased adherence to peritoneal cells and increased ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... and endometrial cancer. Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%. A few ... endometrial or cervical cancer). Although localized pain may occur in advanced cancer, the initial tumor is usually painless. ...
These neoplasms were initially regarded as eosinophilias, hypereosinophilias, Myeloid leukemias, myeloproliferative neoplasms, ... of endometrial cancers (half amplifications, half other types of mutations); ~6% of prostate cancers (half amplifications, half ... Unlike many other myeloid neoplasms with eosinophil such as those caused by Platelet-derived growth factor receptor A or ...
Also known as: Endometrial Neoplasm / Endometrial Neoplasms / Endometrial neoplasia / Endometrial neoplasm NOS / Neoplasm ... Neoplasms, Endometrial Recruiting Phase 1 / 2 Trials for Cisplatin (DB00515). Back to Neoplasms, Endometrial ...
"Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of ... "Endometrial Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms". ...
Vaginal Endometrial Stromal Neoplasm Symptom Checker: Possible causes include Benign Prostatic Hyperplasia. Check the full list ... The endometrial stromal nodule is likewise rare and, actually, is the rarest of endometrial stromal neoplasms. [pubs.sciepub. ... 2015 7 Endometrial stromal nodule of the vaginal wall with a review of vulvovaginal endometrial stromal neoplasms. ( 26076086 [ ... Abstract Endometrial stromal sarcoma rarely occurs as an extrauterine neoplasm and it is even more unlikely to be found in the ...
Breast Neoplasms Endometrial Neoplasms Ovarian Neoplasms Hot Flashes Cardiovascular Diseases Female Urogenital Diseases ISSN. ... Breast Neoplasms Endometrial Neoplasms Ovarian Neoplasms Abstract. Canadian consensus conference on menopause 2006 update No. ... Endometrial Neoplasms - prevention & control Endometrial Neoplasms - diet therapy Food Nutritional Physiological Phenomena ... Endometrial Neoplasms - prevention & control Endometrial Neoplasms - diet therapy Food Nutritional Physiological Phenomena ...
The most common type, endometrial cancer, happens most often in women over 55. Know the signs and symptoms. ... ClinicalTrials.gov: Endometrial Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Uterine Neoplasms (National ... Endometrial cancer (Medical Encyclopedia) Also in Spanish * Uterine Cancer (Centers for Disease Control and Prevention) - PDF ... Stages of Endometrial Cancer (National Cancer Institute) Also in Spanish * Stages of Uterine Sarcoma (National Cancer Institute ...
Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Uterine Diseases. ... Endometrial Neoplasms. Obesity. Overnutrition. Nutrition Disorders. Overweight. Body Weight. ... Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer (FETCH). The safety and scientific validity of this study ... Identify estrogen-response genes in endometrial cancer [ Time Frame: Baseline ]. Omental fat will be collected from 6 lean ...
Endometrial Neoplasms. Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. ... An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer. The safety and scientific validity of ... Endometrial cancer. Recurrent or persistent endometrial carcinoma. Progesterone Receptor Negative. Sodium Cridanimod. ... All patients must have endometrial cancer PrR status determined from an archival sample at Screening. The PrR status (positive ...
Endometrial Neoplasms. Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. ... Endometrial cancer is the most common malignancy of the female reproductive tract. The majority of patients with endometrial ... Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers. ... A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial ...
Endometrial Neoplasms. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Uterine Neoplasms. Genital ... Endometrial cancer. Advanced or Recurrent Endometrial Carcinoma. Metformin. Letrozole. Femara. Everolimus. Afinitor. Zortress. ... Urogenital Neoplasms. Neoplasms by Site. Uterine Diseases. Genital Diseases, Female. Metformin. Everolimus. Letrozole. ... It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells. ...
Endometrial cancer outcomes among non-Hispanic US born and Caribbean born black women.. Schlumbrecht M1, Huang M2, Hurley J2, ... Data on endometrial cancer outcomes among immigrant women in the USA are lacking. The objective was to determine the effect of ... The prevalence of high grade endometrial cancer histologies among black women of Caribbean nativity is higher than previously ... non-Hispanic women with known nativity and treated for endometrial cancer between 2001 and 2017. Sociodemographic, treatment, ...
Endometrial Neoplasms. *. .ysm-shield_svg__ysm-shield-element{fill:currentCollor;stroke:currentCollor}. ...
The role of lymphadenectomy in the management of early endometrial cancer remains controversial. In the recent ESMO-ESGO-ESTRO ... DNA, Neoplasm / genetics * Decision Making * Endometrial Neoplasms / genetics * Endometrial Neoplasms / pathology* * ... Endometrial cancer patients registered in the Swedish Quality Registry for Gynecologic Cancer 2010-2015 with FIGO Stages I-III ... Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On ...
High circulating adiponectin levels are associated with reduced endometrial cancer risk, largely independent of other obesity- ... Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women J Clin Endocrinol Metab. 2007 Jan;92(1): ... Results: Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted relative risk for ... Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial ...
Endometrial Neoplasms. *RR 8.0 for unopposed estrogen-only HRT; Tend to be less invasive than sporadically occurring ... Risk of endometrial Ca with combined estrogen-progestin HRT *Use of HRT with or without progestin was not assd with increased ... Lowers risk of endometrial cancer and hyperplasia compared with estrogen-only HRT, though may still be increased risk c/w women ... higher incidence of endometrial Ca than in the general population (RR 1.69 with 3-5y use), while continuous use was associated ...
Endometrial Neoplasms. D016889. EFO:0004230. endometrial neoplasm. 2. ClinicalTrials. Liver Diseases. D008107. EFO:0001421. ... Stomach Neoplasms. D013274. EFO:0003897. stomach neoplasm. 3. ClinicalTrials. Anus Neoplasms. D001005. EFO:0003835. anal ... Peritoneal Neoplasms. D010534. EFO:1001100. peritoneal neoplasm. 2. ClinicalTrials. Rectal Neoplasms. D012004. EFO:1000657. ... Pancreatic Neoplasms. D010190. EFO:0003860. pancreatic neoplasm. 3. ClinicalTrials. Stomach Neoplasms. D013274. EFO:0000503. ...
Endometrial Neoplasms. D016889. EFO:0004230. endometrial neoplasm. 3. ClinicalTrials. ClinicalTrials. Glioma. D005910. EFO: ... Ovarian Neoplasms. D010051. EFO:0003893. ovarian neoplasm. 3. ClinicalTrials. ClinicalTrials. Pancreatic Neoplasms. D010190. ... Nasopharyngeal Neoplasms. D009303. EFO:0004252. nasopharyngeal neoplasm. 2. ClinicalTrials. Neoplasms. D009369. EFO:0000311. ... Urethral Neoplasms. D014523. EFO:0003846. urethral neoplasm. 3. ClinicalTrials. ClinicalTrials. Uterine Cervical Neoplasms. ...
Keywords: Genital neoplasms, female; radiotherapy, adjuvant; brachytherapy; endometrial neoplasms.. RESUMO. OBJETIVO: Comparar ... Kong A, Johnson N, Cornes P, Simera I, Collingwood M, Williams C, Kitchener H. Adjuvant radiotherapy for stage I endometrial ... Medical literature has not defined the best adjuvant treatment for stage 1A endometrial cancer, histological grades 1 and 21. ... Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients withuterine-confined endometrial ...
... and recent research abstracts relating to endometrial cancer. Endometrial cancer is a malignancy of the endometrium (the inner ... This page has a summary of endometrial cancer, selected links to resources for patients and for health professionals, ... PubMed Central search for free-access publications about Endometrial Cancer. MeSH term: Endometrial Neoplasms. US National ... Home > Cancer Types > Gynecological > Endometrial (Uterus) Cancer Endometrial (Uterus) Cancer. Endometrial cancer is a ...
Keywords : Wnt proteins; Endometrial neoplasms; Women; Postmenopause; Endometrium. · abstract in Portuguese · text in English ... MENEZES, Marina de Pádua Nogueira et al. Canonical and noncanonical Wnt pathways: a comparison between endometrial cancer type ... For this reason, we proposed to evaluate Wnt gene expression in endometrial cancer type I. DESIGN AND SETTING: Cross-sectional ... METHODS: Endometrial specimens were obtained from surgeries performed between 1995 and 2005 at São Paulo Hospital, Universidade ...
Endometrial Neoplasms. Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or ... Endometrial Stromal Tumors. Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain ... Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or ... Black women with endometrial cancer are more likely to die from their disease compared to white women with endometrial cancer. ...
endometrial neoplasm. *obesity. *body mass index. *hormone replacement therapy. Introduction. Endometrial cancer is the most ... Most incident cases of endometrial cancer were initially identified through a self-report of endometrial cancer on any of the ... Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. Marjorie L. McCullough, Alpa V. Patel ... Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8. ...
Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometr ... Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has an excellent ... Endometrial Neoplasms / pathology*, therapy. Fatal Outcome. Female. Humans. Menorrhagia / etiology. Mixed Tumor, Malignant / ... INTRODUCTION: Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has ...
... to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compar ... Endometrial Cancer. *Endometrial cancer. *Follow-up examination. *Endometrial Neoplasms. *Sarcoma, Endometrial Stromal ... Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit?. Trial Phase:. N/A. ... Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit? ...
... recurrent or persistent endometrial cancer. Thalidomide may stop ... Endometrial Neoplasms. .map{width:100%;height:300px;margin- ... Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell ... Histologically confirmed endometrial carcinoma. - Recurrent or persistent (refractory to curative therapy or established. ... progression-free survival, in patients with recurrent or persistent endometrial carcinoma.. II. Determine the nature and degree ...
... as well as myometrial invasion of endometrial cancer was studied. METHODS: The effe ... Colonic Neoplasms / chemistry, pathology. Endometrial Neoplasms / chemistry, enzymology, pathology*. Female. Gelatinases / ... Neoplasm Invasiveness*. Neoplasm Staging. Receptors, Transforming Growth Factor beta / analysis. Tissue Inhibitor of ... Plasma was obtained from 8 endometrial cancer patients with Stage-Ia disease, from 6 with Stage-Ib disease, and from 4 with ...
Estrogen and progesterone signaling in EMT also play key roles in the prognosis of endometrial carcinogenesis. In this review ... leading to endometrial carcinogenesis and distant metastasis. The PI3K/AKT pathway activates the ransforming growth factor beta ... we summarize the current clinical and basic research efforts regarding the detailed molecular regulation in endometrial ... Endometrial carcinogenesis is involved in several signaling pathways and it comprises multiple steps. The four major signaling ...
Uterine sarcoma is another type of endometrial (uterine) cancer. This article addresses risk, diagnosis and treatment of these ... Endometrial (uterine) cancer is the most common gynecological cancer in the US, with an estimated 55,000 new cases each year. ... of all endometrial/uterine neoplasms. There are several subtypes of uterine sarcomas, including low grade endometrial stromal ... How is endometrial cancer treated?. Surgery Almost all women with endometrial cancer will have some type of surgery during the ...
Endometrial Neoplasms Endometrium Female Humans Middle Aged Predictive Value of Tests Uterine Hemorrhage ... Outpatient endometrial biopsy: the pipelle. S N Youssif, D L McMillan Department of Obstetrics and Gynaecology, Whipps Cross ... Outpatient endometrial biopsy: the pipelle. British journal of hospital medicine. 1995 Sep 6-19;54(5):198-201 ... The pipelle endometrial biopsy (EB) is accurate, safe, economical and acceptable to patients, clinicians and pathologists. ...
New development on hysteroscopy for endometrial cancer diagnosis: state of the art. Jose CARUGNO 1 ✉, Staci J. MARBIN 2, ... Endometrial cancer (EC) is the most common gynecologic cancer diagnosed in developed countries and represents the second most ... Hysteroscopic endometrial biopsy is performed under direct visualization and is the only technique that allows for the ... New development on hysteroscopy for endometrial cancer diagnosis: state of the art. Minerva Med 2021;112:12-9. DOI: 10.23736/ ...
KEY WORDS: Sexual dysfunctions, psychological; Quality of life; Endometrial neoplasms. inizio pagina ... Quality of life and sexual functioning of patient affected by endometrial cancer. Stefano CIANCI 1 ✉, Andrea ROSATI 2, Vito A. ... Quality of life and sexual functioning of patient affected by endometrial cancer. Minerva Med 2021;112:81-95. DOI: 10.23736/ ... INTRODUCTION: Thanks to timely diagnosis and medical advancement the number of endometrial cancer (EC) patients achieving long ...
  • 1α,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by Targeting RAC1 and PAK1. (cancerindex.org)
  • Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome. (biomedsearch.com)
  • INTRODUCTION: Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has an excellent prognosis. (biomedsearch.com)
  • Mixed type endometrial carcinoma was diagnosed and she was treated with comprehensive surgery plus adjuvant chemotherapy. (biomedsearch.com)
  • I. Determine the antitumor cytostatic activity of thalidomide, in terms of 6-month progression-free survival, in patients with recurrent or persistent endometrial carcinoma. (knowcancer.com)
  • Individual medical records of patients with preoperative histological diagnosis of endometrial carcinoma from January 2000 to December 2001 were reviewed and the data analysed. (hkmj.org)
  • Since alpha-smooth muscle (alpha-SM) actin positive myofibroblasts characterize the desmoplastic stromal response in a variety of neoplasms , the present study was undertaken in order to establish whether these cells are also prominent in the stroma of endometrioid carcinoma and if present could be used as a valid criterion in the differential diagnosis between benign and malignant lesions. (curehunter.com)
  • The present study of 100 endometrial samples showed focal desmoplastic stromal reaction with alpha-SM actin positive myofibroblasts in 30% of small samples and in 50% of hysterectomy specimens with endometrioid carcinoma . (curehunter.com)
  • Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. (curehunter.com)
  • Clinicopathologic studies in endometrial carcinoma, ovarian neoplasms, and soft tissue tumors. (stanford.edu)
  • The International Agency for Research on Cancer recently estimated that endometrial carcinoma is the commonest gynaecological cancer in the developed world, 1 with a rising incidence in postmenopausal women. (bmj.com)
  • Deletions in 10q22-25 occur in multiple tumor types, most prominently advanced glial tumors (glioblastoma multiforme/anaplastic astrocytoma), but also prostate, endometrial, renal and small cell lung carcinoma, melanoma, and meningioma (see references in refs. (pnas.org)
  • Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. (genome.jp)
  • Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. (genome.jp)
  • Molecular pathogenesis and prognostic factors in endometrial carcinoma. (genome.jp)
  • Prognostic parameters of endometrial carcinoma. (genome.jp)
  • However, molecular testing of these tumors, unlike in endometrial carcinoma, is not routinely used in clinical practice. (cancernetwork.com)
  • Though endometrial carcinoma is the most common gynecologic malignant neoplasm [ 1 ], diagnostic capabilities and management of endometrial precancer (intraepithelial neoplasia) lag far behind those of cervical carcinoma [ 2 ]. (hindawi.com)
  • A neoplastic continuum from simple, to complex, to atypical hyperplasia, to endometrial carcinoma is suggested from longitudinal epidemiologic studies [ 3 - 5 ]. (hindawi.com)
  • Risk of progression to carcinoma among women with a diagnosis of endometrial hyperplasia with atypia is not well understood, though exposure to progestin therapy has been reported to be associated with an approximately 60% decreased risk of progression [ 4 , 8 ]. (hindawi.com)
  • Abushahin N, Zhang T, Chiang S, Zhang X, Hatch K, Zheng W (2011) Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases. (springer.com)
  • RESULTS: An excess of subsequent malignancies after women were diagnosed with endometrial carcinoma was noted at 11 sites. (lu.se)
  • Primary ovarian carcinoma was followed by an increased risk of developing endometrial carcinoma, and the risks of developing many other malignancies also were increased after women were diagnosed with endometrial carcinoma, including intestinal malignancies, renal cell carcinoma, bladder carcinoma, squamous cell skin carcinoma, connective tissue malignancies, and leukemia. (lu.se)
  • when endometrial carcinoma was the subsequent neoplasm, the SIR was 87. (lu.se)
  • A small familial component was found in the cooccurrence of endometrial carcinoma and ovarian carcinoma. (lu.se)
  • The patterns of second neoplasms also suggest that hereditary nonpolyposis colorectal carcinoma may contribute to the association between endometrial and ovarian malignancies. (lu.se)
  • S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. (cancerindex.org)
  • We reported that S100P expression was dramatically elevated in both endometrial squamous cell carcinoma and adenosquamous carcinoma, but not in adenocarcinoma and normal endometrial samples. (cancerindex.org)
  • From November 1977 to July 1987, 300 consecutive patients with endometrial carcinoma clinically confined to the uterine corpus underwent primary surgery consisting of at least abdominal hysterectomy and adnexectomy. (elsevier.com)
  • Uterine serous carcinoma (USC) is an aggressive histologic subtype of endometrial cancer, similar to serous ovarian carcinoma. (termedia.pl)
  • Although USC represents less than 10% of all endometrial cancers, it accounts for more than 50% of relapses and deaths attributed to endometrial carcinoma [ 1 , 2 , 3 ], with an estimated 5-year overall survival of 18-27% of patients with disease outside the uterus [ 4 , 5 ]. (termedia.pl)
  • Detection of malignant ovarian neoplasms: a review of the literature. (nih.gov)
  • A series of investigations on ovarian neoplasms have improved our understanding of proinflammatory microenvironment including unfavorable cytokines, chemokines and imbalanced hormone production. (mdpi.com)
  • Endometrial and ovarian neoplasms crept up more slowly. (scielosp.org)
  • Endometrial carcinogenesis is a complex and multi-step process that features a slow progression from hyperplasia to endometrial cancer [ 1 , 2 ]. (mdpi.com)
  • Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. (nih.gov)
  • Safety was evaluated with peripheral blood samples for hematology, liver and renal function, and lipids, along with vital signs and interval medical evaluations.When compared with estradiol alone, combinations of drospirenone and estradiol were effective in protecting against endometrial hyperplasia. (stanford.edu)
  • Just diagnosed w endometrial adenocarcenoma figo grade 1 with tubulopapillay & mucinous features, in background of endometrial hyperplasia w focal atypia. (cancer.org)
  • This is called endometrial hyperplasia. (northshore.org)
  • Identifying molecular markers of endometrial hyperplasia (neoplasia) progression is critical to cancer prevention. (hindawi.com)
  • Present diagnostic capabilities utilizing histologic evaluation for endometrial hyperplasia/neoplasia alone are limited by poor diagnostic reproducibility [ 7 ] and relatively low prognostic value. (hindawi.com)
  • Future studies that attempt to elucidate molecular biomarkers of endometrial hyperplasia progression risk will require the development of two methodologies: the ability to perform array studies from extremely small fresh endometrial samples, as well as high-fidelity large-scale affordable array interrogation of archived FFPE samples. (hindawi.com)
  • The literature refers to pyometra as the most important pathology in the feline uterus, which is often associated with cystic endometrial disease (cystic endometrial hyperplasia/pyometra complex or CEH-Pyo). (intechopen.com)
  • The cystic endometrial hyperplasia-pyometra (CEH-Pyo) complex is the most frequent and important uterine disorder in queens [ 1 - 5 ]. (intechopen.com)
  • Nevertheless, estrogen's effects in uterus have also been implicated as causing hyperplasia of the endometrium and cystic dilation of endometrial glands, with concomitant increased secretion of fluid that favors the progression of CEH to pyometra [ 6 , 7 ]. (intechopen.com)
  • Methods: We identified 23 women with EBs performed at Mayo Clinic diagnosed as normal (n = 14) or hyperplasia (n = 9) and who later developed endometrial cancer after a median interval of 1 year. (elsevier.com)
  • Cases were matched 1:1 with patients with benign EBs who did not develop EC (controls) by histology of benign EB (normal endometrium vs. endometrial hyperplasia without atypia), date of EB, age at EB, and length of post-biopsy follow-up. (elsevier.com)
  • Breast Neoplasms and 69 others ), proposed to participate in pathways (CARM1 and Regulation of the Estrogen Receptor, Downregulated of MTA-3 in ER-negative Breast Tumors, Pelp1 Modulation of Estrogen Receptor Activity) and processes (androgen metabolic process, antral ovarian follicle growth, epithelial cell development, epithelial cell proliferation involved in mammary gland duct elongation, male gonad development and 12 others ). (nrresource.org)
  • Endometrial cancer is a malignancy of the endometrium (the inner lining of the uterus, or womb) and is the most common gynaecological cancer, and accounts for 13% of all cancers in women. (cancerindex.org)
  • We compared the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin between endometrial cancer type I and atrophic endometrium. (scielo.br)
  • Regarding the survival curve for FZD5 in group B, we did not find any significant association between atrophic endometrium and endometrial adenocarcinoma. (scielo.br)
  • The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. (bioportfolio.com)
  • Most of the major known risk factors for endometrial cancer contribute to prolonged and excessive exposure of the endometrium to estrogens unopposed by progesterone, as occurs with unopposed postmenopausal estrogen therapy and obesity. (aacrjournals.org)
  • Endometrial cancer develops when cells in the endometrium begin to grow out of control. (oncolink.org)
  • Hysteroscopic endometrial biopsy is performed under direct visualization and is the only technique that allows for the selective biopsy of targeted areas of the endometrium. (minervamedica.it)
  • But in most cases of endometrial cancer, the endometrium has built up and has not shed and thinned. (northshore.org)
  • Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). (medlineplus.gov)
  • Histopathological findings of the small nodules showed densely concentrated endometrial stromal cells reminiscent of a proliferative phase endometrium with a concentric arrangement of small spiral arteriole-like vessels. (hindawi.com)
  • and Group B, endometrial adenocarcinoma (n = 45). (scielo.br)
  • METHODS: The effects of TGF-beta 1 on cellular invasiveness, gelatinase activity, and expression of TIMP-1 were examined in 2 endometrial adenocarcinoma cell lines, KLE and Ishikawa. (biomedsearch.com)
  • The most common type of endometrial cancer is called endometrioid adenocarcinoma. (oncolink.org)
  • The second most common form is papillary serous adenocarcinoma (about 10% of all endometrial cancers), and yet another form is clear cell adenocarcinoma (about 4% of all endometrial carcinomas). (oncolink.org)
  • There are a few other rare types like mucinous adenocarcinoma and squamous cell adenocarcinoma that each account for less than 1% of endometrial cancers. (oncolink.org)
  • Alpha-smooth muscle actin-positive myofibroblasts in endometrial stroma are not a reliable criterion for the diagnosis of well differentiated endometrioid adenocarcinoma in small tissue samples. (curehunter.com)
  • Thus the common presence of alpha-SM actin-positive myofibroblasts in normal endometrial stroma and in benign and malignant lesions precludes its usefulness in the diagnosis of well differentiated endometrioid adenocarcinoma , especially in small tissue samples. (curehunter.com)
  • Chiantera V et al (2014) Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients. (springer.com)
  • Progestagen-based contraceptives may be risk factors for the CEH-Pyo syndrome, for endometrial adenocarcinoma and also to mammary tumors in this species. (intechopen.com)
  • Akahira J et al (2006) Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. (springer.com)
  • These neoplasms can be benign or malignant. (childrensmercy.org)
  • Image analysis and multi-layer perceptron artificial neural networks for the discrimination between benign and malignant endometrial lesions. (cancerindex.org)
  • and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL). (bioportfolio.com)
  • The distinction between benign and malignant tumors is very important in endometrial cancer. (oncolink.org)
  • Here, we show that Malignant Brain Tumor Domain-containing Protein 1 (MBTD1), a member of the polycomb group protein family, is critical for human endometrial stromal cell (HESC) decidualization. (frontiersin.org)
  • If a patient has endometrial cancer, undergoes hysterectomy for treatment, and then 5 years later has recurrence of endometrial cancer with metastases to colon, lungs, and lymph nodes, do I still code personal history of endometrial cancer along with the codes for secondary malignant neoplasm of colon, lung, and lymph nodes? (medscape.com)
  • The secondary malignancy code for endometrial cancer is C79.82, secondary malignant neoplasm of genital organs. (medscape.com)
  • Z85.42 is defined as "personal history of malignant neoplasm of other parts of the uterus. (medscape.com)
  • If the primary malignancy has been previously excised or eradicated from its site, and there is no further evidence of disease or treatment directed at that site, use personal history of malignant neoplasm. (medscape.com)
  • Purely mesenchymal tumors, such as those derived from smooth muscle and endometrial stroma, are considered, as are some benign and malignant neoplasms containing mixtures of epithelium and connective tissue. (springer.com)
  • Low-grade endometrial stromal sarcoma (LG-ESS) is a rare malignant disease and demonstrates various patterns in preoperative imaging. (hindawi.com)
  • Outpatient endometrial biopsy: the pipelle. (nextbio.com)
  • The benefits of hysteroscopy in achieving a targeted endometrial biopsy under direct visualization over blind biopsy techniques are widely accepted. (minervamedica.it)
  • Some investigators believe that this should be the first diagnostic procedure because vaginal ultrasonography is less invasive than endometrial biopsy. (medscape.com)
  • One of the difficulties with using the endometrial stripe as a criterion for further diagnostic tests (eg, endometrial biopsy) is that several conditions may be present that yield a false reading on the endometrial stripe. (medscape.com)
  • Although fractional dilatation and curettage was historically the definitive diagnostic procedure to help rule out endometrial cancer, in current practice endometrial biopsy as an office procedure is quick, well tolerated, and quite sensitive for making the diagnosis. (medscape.com)
  • If endometrial pathology is not present on biopsy specimens and the patient has no further bleeding, no additional diagnostic tests need to be performed. (medscape.com)
  • According to the National Cancer Institute (NCI) PDQ cancer information summary for endometrial cancer screening, no evidence suggests that transvaginal sonography reduces mortality from endometrial cancer, and there is inadequate evidence that endometrial sampling (biopsy) reduces mortality. (medscape.com)
  • The endometrial biopsy demonstrated a serous endometrial cancer. (ecancer.org)
  • Objective: To determine whether analysis of methylated DNA in benign endometrial biopsy (EB) specimens is associated with risk of endometrial cancer (EC). (elsevier.com)
  • Objective: The aim of this study was to assess the role of frozen section (FS) in identifying an absence of lymph nodes during sentinel lymph node (SLN) biopsy for apparent early-stage endometrial cancer (EC). (elsevier.com)
  • Topotecan is an active agent in the treatment of advanced and recurrent endometrial cancers. (clinicaltrials.gov)
  • Up to 80% of endometrial and breast cancers express oestrogen receptor alpha (ERα). (bioportfolio.com)
  • Endometrial cancer is the most common female gynecologic cancer in the United States, ranking fourth among all cancers in women in age-adjusted incidence ( 1 ). (aacrjournals.org)
  • Endometrial cancer was among the first cancers identified as being obesity-related. (aacrjournals.org)
  • CONCLUSIONS: Myometrial invasion of endometrial cancers involves an increase in gelatinase activity, regulated to some extent by TGF-beta 1 in an autocrine or paracrine fashion. (biomedsearch.com)
  • This type compromises about 75% of all endometrial cancers. (oncolink.org)
  • They make up about 10% of all endometrial cancers. (oncolink.org)
  • The National Comprehensive Cancer Network (NCCN) guidelines endorse universal immunohistochemistry (IHC) or microsatellite instability (MSI) testing, regardless of family history, on all individuals diagnosed with colorectal or endometrial cancers to identify which patients should have genetic testing for Lynch syndrome. (medscape.com)
  • In 2007, 7536 new endometrial cancers were diagnosed in the UK, making it the fourth most common cancer in women after breast, lung, and colorectal cancers. (bmj.com)
  • Differential analysis of ovarian and endometrial cancers identifies a " by Diana L. Kolbe, Julie A. DeLoia et al. (gwu.edu)
  • 50%) ( 9 ), advanced prostate cancers ( 10 , 11 ), and endometrial carcinomas (30-50%) ( 12 , 13 ). (pnas.org)
  • Women with Lynch syndrome have an autosomal dominant mutation in one of the DNA mismatch repair genes resulting in an increased lifetime risk for colorectal and endometrial cancer in addition to cancers of the ovary, stomach, hepatobiliary tract, pancreas, small bowel, urinary tract, and central nervous system. (ecancer.org)
  • Disability-adjusted life years in women aged 15-44 years were calculated for breast cancer and three female reproductive system cancers (cervical, endometrial and ovarian), by summing years of life lost due to premature mortality and years lived with disability. (scielosp.org)
  • S100P is known to affect tumor development and metastasis of various cancers, but its role in endometrial cancer is unclear. (cancerindex.org)
  • There are several subtypes of uterine sarcomas, including low grade endometrial stromal sarcoma (ESS), high grade ESS, undifferentiated uterine sarcoma (UUS) and uterine leiomyosarcoma (ULMS). (oncolink.org)
  • Diseases associated with MBTD1 include Endometrial Stromal Sarcoma and Endometrial Stromal Nodule . (genecards.org)
  • Abrams J, Talcott J, Corson JM (1989) Pulmonary metastases in patients with low-grade endometrial stromal sarcoma. (springer.com)
  • Agoff SN, Grieco VS, Garcia R, Gown AM (2001) Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. (springer.com)
  • Aisagbonhi O, Harrison B, Zhao L, Osgood R, Chebib I, Oliva E (2017) YWHAE rearrangement in a purely conventional low-grade endometrial stromal sarcoma that transformed over time to high-grade sarcoma: importance of molecular testing. (springer.com)
  • Endometrial stromal sarcoma (ESS) has a reported frequency of approximately 3%-9% of uterine malignancies and 14% of uterine sarcomas [ 1 ]. (hindawi.com)
  • Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. (semanticscholar.org)
  • An endometrial stromal sarcoma cell line with the JAZF1/PHF1 chimera. (semanticscholar.org)
  • Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. (aau.dk)
  • Occult endometrial cancer is occasionally discovered in women with Lynch syndrome undergoing risk-reducing hysterectomy. (ecancer.org)
  • A 50-year-old woman with Lynch syndrome underwent endometrial sampling prior to planned risk-reducing hysterectomy and bilateral salpingo-oophorectomy. (ecancer.org)
  • However, because of high lifetime risk of endometrial cancer in women with Lynch syndrome the NCCN and other consensus guidelines recommend annual or biennial endometrial sampling beginning at age 30-35 years and risk-reducing hysterectomy and bilateral salpingo-oophorectomy in women who have completed childbearing [ 1 , 2 ]. (ecancer.org)
  • We present a case of an asymptomatic patient found on preoperative endometrial sampling to have serous endometrial cancer, raising the question of whether preoperative endometrial sampling should become the standard of care for Lynch patients undergoing risk-reducing hysterectomy. (ecancer.org)
  • To assess RNA and DNA quantity and quality from routinely collected endometrial samples and evaluate the performance of RNA- and DNA-based arrays across endometrial tissue types, we collected fresh frozen (FF) Pipelle, FF curettage, and formalin-fixed paraffin-embedded (FFPE) hysterectomy specimens (benign indications) from eight women. (hindawi.com)
  • Additionally, neoplastic and uninvolved tissues from 24 FFPE archival hysterectomy specimens with endometrial hyperplasias and carcinomas were assessed. (hindawi.com)
  • To address whether the morphological differences seen in these carcinomas represent distinct characteristics at the molecular level we analyzed DNA methylation patterns in 11 papillary serous tumors, 9 endometrioid ovarian tumors, 4 normal fallopian tube samples and 6 normal endometrial tissues, plus 8 normal fallopian tube and 4 serous samples from TCGA. (gwu.edu)
  • Although PTEN mutations are found predominantly in advanced glial and prostate tumors, mutations occur with equal frequency at all stages of endometrial cancer ( 12 ), suggesting that PTEN activation is an early event in endometrial carcinogenesis. (pnas.org)
  • Pseudo-"solid pseudopapillary neoplasms" of the testis: in reality Sertoli cell tumors. (harvard.edu)
  • CONCLUSIONS: The current data show a strong clustering of endometrial carcinomas and ovarian carcinomas, particularly involving tumors of endometrioid morphology. (lu.se)
  • Frequency of known gene rearrangements in endometrial stromal tumors. (semanticscholar.org)
  • Translocations resulting in gene fusion are characteristic of endometrial stromal tumors (ESTs). (semanticscholar.org)
  • Chromosomal aberrations involving this gene are associated with endometrial stromal tumors. (wikipedia.org)
  • The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. (biomedsearch.com)
  • BACKGROUND: Population-based data on subsequent neoplasms after women are diagnosed with endometrial and ovarian carcinomas are limited, particularly regarding specific histologic tumor types. (lu.se)
  • METHODS: The nationwide Swedish Family-Cancer Database of 10.2 million individuals, which includes 19,128 invasive endometrial carcinomas and 19,440 ovarian carcinomas, was used to calculate standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs) for second primary carcinomas. (lu.se)
  • Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. (healthtap.com)
  • It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma. (bioportfolio.com)
  • When estrogen is prescribed for a postmenopausal woman with a uterus , progestin should also be initiated to reduce the risk of endometrial cancer . (rxlist.com)
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (nih.gov)
  • Or should I use the code for endometrial cancer, even though she no longer has a uterus? (medscape.com)
  • Endometrial cancer is also called cancer of the uterus, or uterine cancer. (northshore.org)
  • The main treatment for endometrial cancer is surgery to remove the uterus plus the cervix, ovaries, and fallopian tubes. (northshore.org)
  • If endometrial cancer isn't treated, it may spread outside of the uterus. (northshore.org)
  • This chapter deals with neoplasms of the uterus in which there is mesenchymal differentiation. (springer.com)
  • The categories used here are slightly modified from the comprehensive classification of mesenchymal neoplasms of the uterus developed by the World Health Organization (WHO) (Kurman et al. (springer.com)
  • The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer. (jhppharma.com)
  • The introduction of IHC in diagnostic pathology has revolutionised routine practice, and IHC studies have significantly contributed to a better understanding and subtyping of many malignancies, initially lymphoid neoplasms. (bmj.com)
  • The aim of our study was to evaluate the impact of tumor histology, FIGO grade, DNA ploidy and myometrial invasion (MI) on occurrence of lymph node metastasis (LNM) in patients with endometrial cancer. (nih.gov)
  • The genetic mutation and germline mitochondrial DNA mutations also impair cell proliferation, anti-apoptosis signaling, and epithelial-mesenchymal transition by several transcription factors, leading to endometrial carcinogenesis and distant metastasis. (mdpi.com)
  • Incidence of invasive ovarian Ca, cervical Ca, and endometrial Ca were not sig. (washington.edu)
  • Serum tumor markers in the management of ovarian, endometrial and cervical cancer. (genome.jp)
  • Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometrioid components in a young patient with rapid progression and fatal outcome is presented. (biomedsearch.com)
  • I was referred to a University hospital who changed my pathologt report to serous endometrial carciinoma in a polyp. (cancer.org)
  • The objective is to develop an organotypic model to assess the effects of obesity on the expression and methylation status of estrogen-responsive genes in endometrial cancer. (clinicaltrials.gov)
  • There is no evidence that the use of 'natural' estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (rxlist.com)
  • Estrogen and progesterone signaling in EMT also play key roles in the prognosis of endometrial carcinogenesis. (mdpi.com)
  • 3 ], the factors that contribute to endometrial carcinogenesis during estrogen stimulation include polycystic ovary syndrome (PCOS), obesity, perimenopause, functional tumor, and iatrogenic events. (mdpi.com)
  • Additionally, the NCI's PDQ cancer information summary and ACS agree that for women at increased risk for endometrial cancer due to a history of receiving either estrogen therapy or tamoxifen therapy, there is no indication that routine screening would improve early detection or survival rates. (medscape.com)
  • The NCI's PDQ cancer information summary notes that the use of oral contraceptives containing estrogen and progesterone for at least 1 year reduces the risk for developing endometrial cancer. (medscape.com)
  • When progesterone concentration increases, estrogen action is inhibited in uterine epithelia, and endometrial stromal cell decidualization initiates. (frontiersin.org)
  • The most common cause of type I endometrial cancer is having too much of the hormone estrogen compared to the hormone progesterone in the body. (northshore.org)
  • Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. (nrresource.org)
  • There will be an estimated 61,880 new cases of endometrial cancer diagnosed (3.6 % of all new cancer cases) annually. (oncolink.org)
  • Most cases of endometrial cancer occur between the ages of 60 and 70. (medlineplus.gov)
  • Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted relative risk for the top vs. bottom quartile = 0.56 (95% confidence interval 0.36-0.86), P(trend) = 0.006]. (nih.gov)
  • The patient did not permit any vaginal intervention including endometrial sampling, therefore laparotomy was decided. (biomedsearch.com)
  • Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. (rxlist.com)
  • This is accomplished by placing a small volume of saline into the endometrial cavity and then repeating the vaginal ultrasonogram. (medscape.com)
  • Bristow RE et al (2006) Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. (springer.com)
  • Unexpected vaginal bleeding after menopause is the most common symptom of endometrial cancer. (northshore.org)
  • Before menopause, abnormal bleeding or vaginal discharge is not as likely to be a sign of endometrial cancer. (northshore.org)
  • Of women who have endometrial cancer after menopause, most have vaginal bleeding. (northshore.org)
  • Identification of molecular alterations present in various stages of endometrial neoplasia will provide the basis for early detection and therapeutics [ 6 ]. (hindawi.com)
  • Tissue archives of longitudinal endometrial neoplasia (intraepithelial neoplasm) specimens represent a potentially valuable resource for genomic studies, but they are typically comprised of formalin-fixed paraffin-embedded (FFPE) samples [ 4 , 5 ]. (hindawi.com)
  • mTOR inhibition with a rapamycin analogue demonstrated in vitro antiproliferative activity on endometrial AN3 CA and HEC-1-A tumor cells, and this inhibition of proliferation was found to be concentration dependent. (clinicaltrials.gov)
  • The objective was to determine the effect of Caribbean nativity on outcomes in black women with endometrial cancer compared with women born in the USA, with attention paid to the effects of tumor grade, sociodemographic factors, and treatment approaches. (nih.gov)
  • Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype. (nextbio.com)
  • Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive)for tumor responses (CR + PR) Complete Response (CR): Disappearance of all target lesions. (amazonaws.com)
  • The characteristic presentation of LG-ESS in magnetic resonance imaging (MRI) findings is a tumor that appears as a polypoid endometrial mass with hypointensity at T1-weighted images (WI) and heterogeneous hyperintensity at T2-WI. (hindawi.com)
  • The association of tumor and patient characteristics with an EN was evaluated, and trend analysis to compare the rate of ENs over calendar quarters was performed. (elsevier.com)
  • The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or persistent endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative. (clinicaltrials.gov)
  • MLN0128 is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. (centerwatch.com)
  • A review of the institutional cancer registry was performed to identify black, non-Hispanic women with known nativity and treated for endometrial cancer between 2001 and 2017. (nih.gov)
  • Summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. (washington.edu)
  • Women with Lynch syndrome (hereditary nonpolyposis colorectal cancer) have up to an 80% increased risk for colorectal cancer and a 60% increased risk for endometrial cancer. (medscape.com)
  • Asymptomatic women with a first-degree relative diagnosed with either endometrial or colorectal cancer before age 60 should also be tested. (medscape.com)
  • Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. (genome.jp)
  • Endometrial cancer patients registered in the Swedish Quality Registry for Gynecologic Cancer 2010-2015 with FIGO Stages I-III and verified nodal status were included. (nih.gov)
  • Receipt of adjuvant endometrial cancer treatment according to race: An NRG Oncology/Gynecologic Oncology Group 210 Study. (bioportfolio.com)
  • Endometrial cancer (EC) is the most common gynecologic cancer diagnosed in developed countries and represents the second most frequent gynecologic cancer-related cause of death following ovarian cancer. (minervamedica.it)
  • In 2014, the American College of Obstetricians and Gynecologists (ACOG) and the Society of Gynecologic Oncology (SGO) published joint guidelines that recommend that all women who are diagnosed with endometrial cancer should be screened for Lynch syndrome. (medscape.com)
  • This topic focuses on type I endometrial cancer, which is the most common kind of uterine cancer. (northshore.org)
  • Register the Administrator's establishing the WTC Health Program site uterine cancer, including its determination not to publish such a within the Department of Health and subtype, endometrial cancer, to the List. (cdc.gov)
  • We presented a narrative review of the current role of hysteroscopy for the diagnosis of endometrial cancer. (minervamedica.it)
  • A high index of suspicion must be maintained if a diagnosis of endometrial cancer is considered. (medscape.com)
  • Adiponectin, an adipocytokine secreted by adipose tissue, is decreased in obesity, insulin resistance, type 2 diabetes, and polycystic ovary syndrome, all of which are well-established risk factors for endometrial cancer. (nih.gov)
  • The majority of women diagnosed with endometrial cancer have already gone through menopause, although it can occur in younger women as well. (oncolink.org)
  • In addition, Lynch syndrome genetic testing should be done for all women diagnosed with endometrial cancer before age 50 and family members of anyone with Lynch syndrome. (medscape.com)
  • The patient underwent a pelvic ultrasound which demonstrated an 8 mm endometrial echo with heterogeneity, likely representing small benign endometrial polyps. (ecancer.org)
  • Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive) by evaluating progression-free survival Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. (amazonaws.com)
  • Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial cancer during an average of 5.1 yr of follow-up. (nih.gov)
  • Ultrasound Scoring of Endometrial Pattern for Fast-Track Identification or Exclusion of Endometrial Cancer in Women with Postmenopausal Bleeding. (bioportfolio.com)
  • To evaluate the Risk of Endometrial Cancer (REC) scoring system for the prediction of high and low probability of endometrial cancer (EC) in women with postmenopausal bleeding (PMB). (bioportfolio.com)
  • Epidemiologic studies unequivocally show that greater body mass increases the risk of endometrial cancer, but whether risk varies by use of postmenopausal hormone therapy (HT), location of fat deposition, or cancer subtype is still unclear. (aacrjournals.org)
  • The increased risk of endometrial cancer across the range of BMI in women who never used postmenopausal HT stresses the need to prevent both overweight and obesity in women. (aacrjournals.org)
  • Postmenopausal hormone replacement therapy: endometrial and breast effects. (genome.jp)
  • Ali RH et al (2014) Molecular characterization of a population-based series of endometrial stromal sarcomas in Kuwait. (springer.com)
  • Rearrangements of JAZF1, SUZ12, PHF1, and EPC1 have been reported in endometrial stromal nodules (ESNs), endometrial stromal sarcomas (ESSs), and rarely in undifferentiated endometrial sarcomas (UESs). (semanticscholar.org)
  • Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. (semanticscholar.org)
  • JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin-embedded tissue. (semanticscholar.org)
  • ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. (healthtap.com)
  • Although the prevalence of occult endometrial cancer at the time of risk-reducing surgery in women with Lynch syndrome remains unknown, preoperative endometrial sampling may allow for improved patient counselling and surgical planning in this population, and can help avoid a subsequent surgery for staging. (ecancer.org)
  • Background: In the staging of endometrial cancer, controversy remains regarding the role of sentinel lymph node mapping compared with other nodal assessment strategies. (elsevier.com)
  • Sentinel lymph mapping may be considered an alternative standard of care in the staging of women with endometrial cancer. (elsevier.com)
  • whole exome sequencing and mutation detection have led to identification of potential driver cancer genes in endometrial cancer [ 9 , 10 ]. (hindawi.com)
  • Third is the question of whether BMI differentially affects the two main subtypes of endometrial cancer. (aacrjournals.org)
  • To evaluate the use of a laparoscopic approach for the management of endometrial cancer. (hkmj.org)
  • Objective: We conducted a systematic review to evaluate the diagnostic accuracy and clinical impact of sentinel lymph node mapping in the management of endometrial cancer. (elsevier.com)
  • Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. (springer.com)
  • Diagnostic hysteroscopy for endometrial cancer. (medscape.com)
  • This article is a summary of Chap. 9 on "Surveillance/Recurrence/Metastases of Endometrial Cancer" and is a clinically oriented abbreviated version, which includes recommendations for investigation modalities in aftercare and treatment options in cases of recurrence. (springer.com)
  • Diagnosis of pre cancer cells Endometrial intraepithelial neoplasm May. (cancer.org)
  • Endometrial specimens were obtained from surgeries performed between 1995 and 2005 at São Paulo Hospital, Universidade Federal de São Paulo. (scielo.br)